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A B S T R A C T
Background
Uveitis is a term used to describe a heterogeneous group of intraocular inflammatory diseases of the anterior, intermediate, and posterior
uveal tract (iris, ciliary body, choroid). Uveitis is the fifth most common cause of vision loss in high-income countries, accounting for
5% to 20% of legal blindness, with the highest incidence of disease in the working-age population.
Corticosteroids are the mainstay of acute treatment for all anatomical subtypes of non-infectious uveitis and can be administered orally,
topically with drops or ointments, by periocular (around the eye) or intravitreal (inside the eye) injection, or by surgical implantation.
Objectives
To determine the efficacy and safety of steroid implants in people with chronic non-infectious posterior uveitis, intermediate uveitis,
and panuveitis.
Search methods
We searched CENTRAL (which contains the Cochrane Eyes and Vision Trials Register) (Issue 10, 2015), Ovid MEDLINE, Ovid
MEDLINE In-Process and OtherNon-Indexed Citations, OvidMEDLINEDaily, OvidOLDMEDLINE (January 1946 toNovember
2015), EMBASE (January 1980 to November 2015), PubMed (1948 to November 2015), Latin American and Caribbean Health
Sciences Literature Database (LILACS) (1982 to November 2015), the metaRegister of Controlled Trials (mRCT) (www.controlled-
trials.com) (last searched 15 April 2013), ClinicalTrials.gov (www.clinicaltrials.gov), and the World Health Organization (WHO)
International Clinical Trials Registry Platform (ICTRP) (www.who.int/ ictrp/search/en).We did not use any date or language restrictions
in the electronic search for studies. We last searched the electronic databases on 6 November 2015.
We also searched reference lists of included study reports, citation databases, and abstracts and clinical study presentations from
professional meetings.
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Selection criteria
We included randomized controlled trials comparing either fluocinolone acetonide (FA) or dexamethasone intravitreal implants with
standard-of-care therapy with at least six months of follow-up after treatment. We included studies that enrolled participants of all ages
who had chronic non-infectious posterior uveitis, intermediate uveitis, or panuveitis with vision that was better than hand-motion.
Data collection and analysis
Two review authors independently reviewed studies for inclusion. Two review authors independently extracted data and assessed the
risk of bias for each study.
Main results
We included data from two studies (619 eyes of 401 participants) that compared FA implants with standard-of-care therapy. Both
studies used similar standard-of-care therapy that included administration of prednisolone and, if needed, immunosuppressive agents.
The studies included participants from Australia, France, Germany, Israel, Italy, Portugal, Saudi Arabia, Spain, Switzerland, Turkey,
the United Kingdom, and the United States. We assessed both studies at high risk of performance and detection bias.
Only one study reported our primary outcome, recurrence of uveitis at any point during the study through 24 months. The evidence,
judged as moderate-quality, showed that a FA implant probably prevents recurrence of uveitis compared with standard-of-care therapy
(risk ratio (RR) 0.29, 95% confidence interval (CI) 0.14 to 0.59; 132 eyes). Both studies reported safety outcomes, and moderate-
quality evidence showed increased risks of needing cataract surgery (RR 2.98, 95% CI 2.33 to 3.79; 371 eyes) and surgery to lower
intraocular pressure (RR 7.48, 95% CI 3.94 to 14.19; 599 eyes) in the implant group compared with standard-of-care therapy through
two years of follow-up. No studies compared dexamethasone implants with standard-of-care therapy.
Authors’ conclusions
After considering both benefits and harms reported from two studies in which corticosteroids implants were compared with standard-
of-care therapy, we are unable to conclude that the implants are superior to traditional systemic therapy for the treatment of non-
infectious uveitis. These studies exhibited heterogeneity in design and outcomes that measured efficacy. Pooled findings regarding safety
outcomes suggest increased risks of post-implant surgery for cataract and high intraocular pressure compared with standard-of-care
therapy.
P L A I N L A N G U A G E S U M M A R Y
Steroid implants for chronic uveitis not caused by infection
Background
Uveitis describes a group of eye diseases caused by inflammation (redness and swelling, etc.). Uveitis is the fifth most common cause of
vision loss in high-income countries, accounting for 5% (1 in 20 cases) to 20% (1 in 5 cases) of blindness, with the disease affecting
mostly working-age people. In low-income countries, uveitis accounts for 2.4% (1 in 40 cases) to 24% (1 in 4 cases) of legal blindness.
These figures are for all types of uveitis (infectious and non-infectious uveitis), so the prevalence of non-infectious uveitis (the focus of
this review) is likely lower than these estimates.
In this review, we were only able to focus on posterior uveitis, which occurs in a region in the back of the eye and may affect the choroid,
retina, and/or vitreous. Posterior uveitis alone accounts for approximately 15% to 22% (1 in 4 to 6 cases) of uveitis cases and leads
to approximately 10% (1 in 10 cases) of legal blindness in the United States. Posterior uveitis is primarily treated either with systemic
(whole body, either by mouth or injection) or local (just near or inside the eye) medications that reduce inflammation, such as steroids.
Review question
We compared steroid devices implanted directly into the eye with standard-of-care therapy for non-infectious posterior uveitis. We
examined whether the steroid implants were better at treating uveitis, had fewer side effects, or both, than standard-of-care therapy.
Study characteristics
We included two randomized controlled trials that compared fluocinolone acetonide implants with standard-of-care therapy. These
studies included 401 participants from Australia, France, Germany, Israel, Italy, Portugal, Saudi Arabia, Spain, Switzerland, Turkey, the
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United Kingdom, and the United States who were 6 years old or older and were followed for two years. The evidence is current to 6
November 2015.
Key results
Since the two studies were designed to answer slightly different questions about the fluocinolone implant, we were not able to combine
data from both studies to compare how well the medications worked. However, we were able to do a combined analysis of the common
side effects, which suggest that participants in the steroid implant group had more surgery for cataract (clouding of the lens of the eye)
and for high eye pressure than participants in the non-implant group. We were unable to determine whether the steroid implants were
better than standard-of-care therapy.
Quality of the evidence
The overall quality of the presently available published evidence was moderate. This finding indicates that future published research is
likely to have an important impact on the conclusions currently provided in this review.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Fluocinolone acetonide compared with systemic therapy for chronic non- infectious uveitis
Patient or population: part icipants with chronic non-infect ious uveit is
Settings: worldwide
Intervention: f luocinolone acetonide implant
Comparison: standard-of -care therapy
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Eyes
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk* Corresponding risk
Standard-of-care ther-
apy* *
Fluocinolone
acetonide implant
Recurrence of uveit is at
24 months
676 per 1000 196 per 1000 (95 to
399)
RR 0.29, (0.14 to 0.59) 132 eyes (1 study) ⊕⊕⊕©
moderate1
Best-corrected visual
acuity (BCVA)
At 12 months, the mean
BCVA in the control
group, as measured by
logMAR chart, was 3.33
letters
At 24 months, the mean
BCVA in the control
group, as measured by
logMAR chart, was 3.23
letters
At 12 months, the mean
BCVA in the control
group, as measured by
logMAR chart, was 1.29
letters more (2.32 lower
to 5.01 higher)
At 24 months, the mean
BCVA in the control
group, as measured by
logMAR chart, was 2.79
letters more (1.16 lower
to 6.88 higher)
12 months; MD 1.29 (-
2.32 to 5.01)
24 months; MD 2.79 (-
1.16 to 6.88)
132 eyes (1 study) ⊕⊕⊕©
moderate1
At 12 months, the
change in BCVA as mea-
sured by logMAR, f rom
baseline 4.61 (SD = 1.38)
let ters in the FA implant
group, compared to 3.33
(SD = 1.23) let ters in the
systemic therapy group.
Number of part icipants
in each group was not
reported
At 24 months, the
change in BCVA as mea-
sured by logMAR, f rom
baseline 6.03 (SD = 1.41)
let ters in the FA implant
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group, compared to 3.23
(SD = 1.41) let ters in the
systemic therapy group.
Number of part icipants
in each group was not
reported
Cataract surgery
through 24 months
274 per 1000 817 per 1000
(638 to 1038)
RR 2.98 (2.33 to 3.79) 371 eyes (2 studies) ⊕⊕⊕©
moderate1
Ele-
vated intraocular pres-
sure > 10 mmHg over
baseline or receiving in-
tervent ion (eye drops
or surgery) through 24
months
144 per 1000 817 per 1000 (390 to
701)
RR 3.64 (2.71 to 4.87) 605 eyes (2 studies) ⊕⊕⊕©
moderate1
Endophthalm it is
through 24 months
0 per 1000 20 per 1000
(8 to 31)* * *
RR 7.30 (0.91 to 58.72) 607 eyes (2 studies) ⊕©©©
very low1,2
Retinal detachment
through 24 months
10 per 1000 21 per 1000
(5 to 84)
RR 2.07 (0.51 to 8.40) 606 eyes (2 studies) ⊕©©©
very low1,2
* The basis for the assumed risk is the mean baseline risk f rom the studies in the meta-analysis; the total number of events in the control group divided by the total number of
part icipants in the control groups scaled to 1000. The corresponding risk (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the
relative effect of the intervent ion (and its 95% CI).
* * * The corresponding risk was the absolute risk (number of events divided by number of part icipants in the intervent ion group). The 95% CI was calculated using a binomial
distribut ion.
CI: conf idence interval; FA: f luocinolone acetonide; M D: mean dif ference; RR: risk rat io; SD: standard deviat ion
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
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∗∗Standard-of -care therapy include systemic steroids, intravitreal steroids, disease-modif ying ant irheumatic drugs (See
Characterist ics of included studies for specif ic details).
1Downgraded for high probability of funding bias or lim itat ions in the design and implementat ion of available studies
(suggest ing high likelihood of performance and detect ion bias) or both.
2Imprecision of results (wide conf idence intervals).
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
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B A C K G R O U N D
Description of the condition
Uveitis is a term used to describe a heterogeneous group of in-
traocular inflammatory diseases of the anterior, intermediate, and
posterior uveal tract (iris, ciliary body, choroid). Uveitis is the
fifth most common cause of vision loss in high-income coun-
tries, accounting for 5% to 20% of legal blindness (Durrani 2004;
Nussenblatt 1990), with the highest incidence of disease in the
working-age population (Suttorp-Schulten 1996). In low-income
countries, uveitis accounts for 2.4% to 24% of legal blindness.
Individual estimates are not available for the various causes of in-
fectious uveitis, including onchocerciasis, the fifth-leading cause
of blindness worldwide (Durrani 2004; Suttorp-Schulten 1996).
A recent, large cross-sectional study (over a 12-month period) by
Gritz and colleagues in California reported the incidence of uveitis
to be 52.4 per 100,000 person-years (Gritz 2004), which was
three times higher than previous estimates. Posterior uveitis alone
accounts for approximately 15% to 22% of uveitis cases in the
United States, and leads to approximately 10% of legal blindness
in the United States (Suttorp-Schulten 1996).
Description of the intervention
Corticosteroids are the mainstay acute treatment for all anatomi-
cal subtypes of non-infectious uveitis. They can be administered
orally, topically with drops or ointments, by periocular (around the
eye) or intravitreal (inside the eye) injection, or by surgical implan-
tation (Haupert 2000). Corticosteroids are immunosuppressant
medications that reduce inflammation andmacular edema (retinal
swelling), a principal cause of reduced vision in uveitis. Treatment
of posterior uveitis represents a particular therapeutic challenge
because topical steroids rarely reach therapeutic concentrations in
the vitreous, thus these patients often require administration of
oral corticosteroids or local steroid injection (Jaffe 2006a). These
therapeutic modalities may lead to several complications includ-
ing cataract formation and elevated intraocular (eye) pressure. The
systemic morbidity associated with oral steroids includes hyper-
glycemia (high blood sugar or frank diabetes mellitus), myopathy
(muscle damage), secondary infections, impaired wound healing,
mental status changes (ranging from mood changes to psychosis),
and adrenal suppression (hormone problems). Periocular and in-
travitreal steroid injections also have limitations: they provide only
short-term control, often requiring repeated injections every three
to six months to control inflammation, and the injection proce-
dure may be complicated by globe perforation, retinal tears, hem-
orrhage, endophthalmitis (infection of the eye), ptosis (drooping
lid), and fibrosis (Haupert 2000; Jager 2004). In addition to sys-
temic corticosteroids, systemic immunomodulatory therapies in-
cluding methotrexate, azathioprine, mycophenolate mofetil, cy-
closporine, adalimumab, infliximab, and alkylating agents such as
cyclophosphamide are used to treat uveitis. There is currently no
standardized algorithm for the use of systemic immunosuppres-
sive therapies for non-infectious uveitis, and most specific agents
are being used off-label for this indication. Additionally, many of
these therapies can have serious side effects including increased
susceptibility to infection and certain types of cancers, as well as
bone marrow suppression (low blood counts, poor blood clotting,
decreased ability to fight infection). While these therapies require
close monitoring, their long-term side effect profiles may be more
favorable than corticosteroids. None of these therapies are avail-
able for localized administration to the eye, with the exception
of cyclosporine, which is approved for dry eye syndrome but not
commonly used to treat uveitis.
How the intervention might work
Several clinical trials have recently investigated the efficacy of a
novel technology that involves corticosteroid delivery via a sur-
gically implanted, intravitreal, polymer-coated, sustained-release
implant (Callanan 2008b; Jaffe 2000a; Jaffe 2005b; Jaffe 2006a;
Lowder 2011b; Williams 2009a). An intravitreal corticosteroid
implant has the theoretical advantage of maintaining an adequate,
relatively stable concentration of corticosteroids for several months
or years without repeated intravitreal injection and its inherent
risks. Such an implant may decrease or eliminate the need for sys-
temic immune suppression.
The first corticosteroid implant for uveitis to be approved by
the US Food and Drug Administration (FDA) was the fluo-
cinolone acetonide sustained-release implant (Retisert, Bausch
& Lomb Inc., Rochester, NY) (Callanan 2008b; Jaffe 2006a;
Kempen 2011a; Pavesio 2010a). Additionally, the FDA has ap-
proved a biodegradable dexamethasone intravitreal steroid implant
for macular edema caused by retinal vein occlusions and diabetic
macular edema (Ozurdex, Allergan Inc., Irvine, CA) for uveitis
(Haller 2010; Taylor 2010). There is also a non-biodegradable
fluocinolone acetonide implant for diabetic edema (Campochiaro
2010), which has been investigated for posterior uveitis. While
such implants may reduce the overall systemic impact of corti-
costeroids, the increased intraocular exposure may cause higher
rates of cataract and glaucoma (Bollinger 2011; Goldstein 2007a;
Kempen2011a; Pavesio 2010a), and these risks need to beweighed
against their potential benefits.
Why it is important to do this review
To date, there are no systematic reviews examining the efficacy
and safety of steroid implants for controlling posterior uveitis-re-
lated inflammation. This review is needed to allowdecisionmakers
(policymakers, clinicians, and patients) to weigh the benefits and
risks of these therapies in choosing the best option for treatment of
uveitis. Furthermore, these implants are expensive (Mohammad
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2007), with the permanent fluocinolone acetonide implant (Re-
tisert) costing approximately USD 18,000.
O B J E C T I V E S
To determine the efficacy and safety of steroid implants in people
with chronic non-infectious posterior uveitis, intermediate uveitis,
and panuveitis.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included unpublished and published randomized controlled
trials (RCTs) with at least six months of follow-up after treatment.
Types of participants
We included studies that enrolled participants with better than
hand-motion vision and history of chronic posterior uveitis, in-
termediate uveitis, or panuveitis (one eye with history of recurrent
non-infectious uveitis affecting the posterior segment for at least
one year) requiring systemic corticosteroids for more than one
month or multiple sub-Tenon’s capsule corticosteroid injections.
We included studies with both active and quiescent disease. We
excluded RCTs that enrolled participants with infectious uveitis.
The participant age inclusion criterion reflects a change from our
protocol, in which we proposed to include only studies that en-
rolled participants 18 years of age or older. We eliminated the age
restriction because no studies qualified for our review that used the
original inclusion criteria, as discussed in the ’Differences between
protocol and review’ section.
Types of interventions
We included studies comparing fluocinolone acetonide or dexam-
ethasone intravitreous implants with standard-of-care therapy (for
example systemic steroids, intravitreal steroids, disease-modifying
antirheumatic drugs). These implants may have been used along-
side traditional topical or systemic anti-inflammatory therapies, as
long as the dosage was stable at the time of enrollment, reflecting
the fact that these medications are used both as monotherapy and
add-on therapy.
Types of outcome measures
Primary outcomes
The primary outcome was the proportion of participants with a
recurrence of uveitis at 6 months. We defined recurrence as any of
the following:
• increase in vitreous haze by two or more steps above
baseline;
• increase in anterior chamber cell by two or more steps
above baseline;
• need to add or increase dose of systemic anti-inflammatory
medication to control inflammation.
Secondary outcomes
Secondary outcomes assessed at 6 months included:
1. mean difference in best-corrected distance visual acuity
(BCVA) as measured by the Early Treatment of Diabetic
Retinopathy Study (ETDRS) chart, Snellen chart, or Snellen
equivalent. (If a study used any other visual acuity chart, we
would seek and verify justification for its use and validation of
the chart compared to the ETDRS/Snellen chart);
2. mean difference in quality of life (mean difference in any
validated measures presented, e.g. National Eye Institute Visual
Functioning Questionnaire (NEI-VFQ), 36-Item Short Form
Health Survey (SF-36));
Adverse events
We assessed the proportion of participants who experienced the
following conditions through 24 months:
• cataract formation/progression or surgery;
• elevated intraocular pressure > 10 mmHg over baseline or
receiving intervention (eye drops or surgery);
• endophthalmitis;
• retinal tear or retinal detachment;
• systemic adverse events related to steroid or
immunomodulatory therapy.
We also evaluated outcomes at times point after 6 months when
provided in the source studies and summarized other adverse
events reported in the included studies. We were presented with
multiple measurements of quality of life and chose to present data
measured by NEI-VFQ. When numeric data was not reported,
we did not abstract data from figures.
Search methods for identification of studies
Electronic searches
We searched CENTRAL (which contains the Cochrane Eyes
and Vision Trials Register) (Issue 10, 2015), Ovid MEDLINE,
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Ovid MEDLINE In-Process and Other Non-Indexed Citations,
Ovid MEDLINE Daily, Ovid OLDMEDLINE (January 1946
to November 2015), EMBASE (January 1980 to November
2015), PubMed (1948 to November 2015), Latin American
and Caribbean Health Sciences Literature Database (LILACS)
(1982 to November 2015), the metaRegister of Controlled Tri-
als (mRCT) (www.controlled-trials.com) (last searched 15 April
2013), ClinicalTrials.gov (www.clinicaltrials.gov), and the World
Health Organization (WHO) International Clinical Trials Reg-
istry Platform (ICTRP) (www.who.int/ictrp/search/en). We did
not use any date or language restrictions in the electronic search
for studies. We last searched the electronic databases on 6 Novem-
ber 2015.
See: Appendices for details of search strategies for CENTRAL
(Appendix 1),MEDLINE (Appendix 2), EMBASE (Appendix 3),
PubMed (Appendix 4), LILACS (Appendix 5),mRCT (Appendix
6), ClinicalTrials.gov (Appendix 7), and the ICTRP (Appendix
8).
Searching other resources
We searched the reference lists of included studies to identify any
additional studies. We also used Google Scholar, Scopus, and the
Science Citation Index Expanded database to identify additional
studies that may have cited any studies we included in the review.
We searched the online files of meeting abstracts for the following
organizations, for years not included in CENTRAL at the time
of the searches: American Academy of Ophthalmology, American
Academy of Optometry, and Association for Research in Vision
and Ophthalmology.
Data collection and analysis
Selection of studies
Two review authors (CJB and ER) independently reviewed the ti-
tles and abstracts (when available) of all records identified through
the electronic and manual searches. For studies that appeared to
meet the inclusion criteria, or for which the information provided
in the title and abstract were insufficient for us to make a clear
decision, we obtained the full-text reports. Two review authors
(CJB and ER) independently assessed the full-text reports to es-
tablish whether the studies met the inclusion criteria. We resolved
any disagreement at either stage of screening by discussion. All
publications from studies meeting the inclusion criteria under-
went assessment of risk of bias and data extraction. We recorded
studies that were excluded after screening the full-text report or
subsequent stages of the review process in the Characteristics of
excluded studies table, with reasons for exclusion documented.
Data extraction and management
Two review authors (CJB and JT) independently extracted the data
for study design, participant characteristics, and the primary and
secondary outcomes onto electronic data collection forms devel-
oped in collaboration with the Cochrane Eyes and Vision Group.
We resolved discrepancies by discussion. We contacted authors of
included studies for missing data. One review author (CJB) en-
tered all data into RevMan 5 (RevMan 2014).
For each study we recorded the following:
• year of publication, country from which participants were
recruited, and source of study funding;
• details of the participants, including demographic
characteristics and criteria for inclusion;
• details of the type of intervention;
• details of the outcomes reported, including method of
assessment and time intervals.
Assessment of risk of bias in included studies
Two review authors (CJB and JT) independently assessed the risk
of bias of included studies as part of the data extraction process.
We followed the tool for assessing risk of bias set out in Chapter
8 of the Cochrane Handbook for Systematic Reviews of Interventions
(Higgins 2011).
We examined seven main criteria:
1. sequence generation;
2. allocation concealment before randomization;
3. masking of participants and study personnel;
4. masking of outcome assessors;
5. incomplete outcome data;
6. selective outcome reporting; and
7. funding source other sources of bias.
We judged whether each study met the respective criterion and
categorized the studies as being at “high risk of bias” (plausible
bias that seriously weakens confidence in the results), “low risk
of bias” (plausible bias unlikely to seriously alter the results), and
“unclear risk of bias” (lack of information or uncertainty over the
potential for bias).
We resolved disagreements through discussion, involving a third
review author as an adjudicator as appropriate.
Measures of treatment effect
Continuous data
For continuous outcomes (visual acuity and quality of life), we
expressed the estimates of treatment effects as mean differences in
themean change frombaseline to follow-up between interventions
with 95% confidence intervals.
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Dichotomous data
For dichotomous outcomes, we expressed the estimates of treat-
ment effects as summary risk ratios with 95% confidence inter-
vals. These outcomes included the recurrence of posterior uveitis,
intermediate uveitis, or panuveitis; elevated intraocular pressure
requiring intervention; need for additional therapeutic modalities
to control inflammation; cataract formation; cataract extraction;
endophthalmitis; retinal tear or retinal detachment; other ocular
complications of uveitis and of therapy; and potential systemic
complications of therapy.
Unit of analysis issues
The unit of analysis was a single eye for the majority of outcomes:
recurrence rate of posterior uveitis, intermediate uveitis, or panu-
veitis; visual acuity; elevated intraocular pressure requiring inter-
vention; reduction of cystoid macular edema; need for additional
therapeutic modalities to control inflammation; cataract forma-
tion; cataract extraction; endophthalmitis; retinal tear or retinal
detachment. The unit of analysis was the person for quality of life
outcomes and potential systemic complications of therapy.
Dealing with missing data
We attempted to contact study investigators for any missing data.
As study investigators did not respond, in Pavesio 2010, or were
not able to provide any additional data, in Kempen 2011, we
extracted data as available from the published report. We did not
impute data for the purposes of this review.
Assessment of heterogeneity
We assessed the included studies for both clinical and method-
ological diversity and present any variability identified in the text.
We assessed statistical heterogeneity using the I2 statistic. We con-
sidered an I2 statistic greater than 50% to indicate substantial sta-
tistical heterogeneity. We took into account clinical, methodolog-
ical, and statistical heterogeneity when considering meta-analysis.
Assessment of reporting biases
We assessed selective outcome reporting by comparing the out-
comes specified in the methods section of the study report with
the data that were reported in the study results. If in updates of
this review 10 or more studies are included, we plan to use a funnel
plot to evaluate for publication bias.
Data synthesis
Data analysis followed the guidelines set out in Chapter 9 of the
Cochrane Handbook for Systematic Reviews of Interventions (Deeks
2011). We calculated a summary risk ratio for dichotomous out-
comes and a summary mean difference for continuous outcomes.
Since there was a small number of studies in the analysis (two), we
used the fixed-effect model.
Subgroup analysis and investigation of heterogeneity
We did not conduct subgroup analyses due to the small number
of included studies and methodologic heterogeneity.
Sensitivity analysis
We did not conduct sensitivity analyses due to the small number
of included studies and methodologic heterogeneity.
Summary of findings
We provided a ’Summary of findings’ table, which includes the
assumed risk and corresponding risk for relevant outcomes based
on the risk across control groups in the included studies. We
graded the overall quality of the evidence for each outcome using
theGRADE classification (www.gradeworkinggroup.org/).We as-
sessed the quality of evidence for each outcome as “high,” “mod-
erate,” “low.” or “very low” according to the following criteria as
described in Chapter 12 of the Cochrane Handbook for Systematic
Reviews of Interventions (Schünemann 2011):
1. High risk of bias among included studies.
2. Indirectness of evidence.
3. Unexplained heterogeneity or inconsistency of results.
4. Imprecision of results (i.e. wide confidence intervals).
5. High probability of publication bias.
R E S U L T S
Description of studies
Results of the search
We retrieved 3318 records from the electronic database search as of
6 November 2015. We identified an additional 124 records from
other sources (Figure 1). After removing duplicates, we screened
2741 unique records and excluded 2684. Fifty-seven records un-
derwent full-text review, and 45 studies (46 full-text reports) were
excluded for the reasons listed in the Characteristics of excluded
studies table. We included two studies from 11 full-text reports.
We did not identify any other relevant studies for this review by
searching reference lists or the Science Citation Index (as of 1 De-
cember 2015).
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Figure 1. Study flow diagram.
Included studies
Wehave provided a detailed description of the individual included
studies in the Characteristics of included studies table. We have
summarized the study characteristics in the following sections.
Types of participants
Both included studies enrolled participants with a clinically simi-
lar diagnosis of non-infectious posterior uveitis, but with slightly
different study populations: Pavesio and colleagues enrolled par-
ticipants who had clinically quiet non-infectious posterior uveitis,
while Kempen and colleagues enrolled participants who had ac-
tive non-infectious posterior uveitis in the study eye at the time of
randomization. Together the included studies enrolled 401 par-
ticipants from Australia, France, Germany, Israel, Italy, Portugal,
Saudi Arabia, Spain, Switzerland, Turkey, the United Kingdom,
and the United States; Pavesio 2010 enrolled 255 participants and
Kempen 2011 enrolled 146 participants. Participants in the two
studies were similar in age (mean age of about 40 years), visual
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acuity, and baseline intraocular pressure. However, Kempen 2011
(75.0%) had a higher percentage of women than Pavesio 2010
(58.2%). Both Pavesio 2010 and Kempen 2011 included par-
ticipants with unilateral disease and asymmetric bilateral disease.
For participants with unilateral disease, the affected eye was the
study eye. However each study handled participants with bilateral
disease differently; for Pavesio 2010 the study eye was the more
severely affected eye, compared with Kempen 2011 where both
eyes were study eyes. Pavesio 2010 did not report the percentage of
participants with asymmetric bilateral disease. In Kempen 2011,
the percentage of participants with asymmetric bilateral disease
was 90% and 46% for FA implant group and standard-of-care
therapy group, respectively.
Types of interventions
Both studies used 0.59mgfluocinolone acetonide (FA) intravitreal
implant as their intervention group and had similar standard-of-
care therapy comparison groups. See Characteristics of included
studies for each study’s description of the standard-of-care therapy
used.
Types of outcomes
Primary outcomes
Pavesio and colleagues were the only study investigators who re-
ported on our primary outcome, recurrence of uveitis. However,
the authors did not report the outcome at 6 months post-treat-
ment, but at 12 and 24 months post-treatment. We assessed the
primary outcome at 12 and 24 months post-treatment.
Secondary outcomes
Kempen and colleagues did not report mean change in BCVA
from baseline at 6 months, but reported it at 12 and 24 months
post-treatment. Pavesio and colleagues reported the proportion
of participants with a visual acuity improvement (more than 15
letters onEarly TreatmentDiabetic Retinopathy Study charts from
baseline), but did not report the distance between the participants
and the charts during the visual acuity assessment. We therefore
could not combine the data. See Table 1.
Only the Kempen study reported on quality of life outcomes.
The study used two different instruments to measure quality of
life; the National Eye Institute Visual Functioning Questionnaire
(NEI-VFQ) and the Short Form (36)Health Survey (SF-36).Data
were presented as mean changes from baseline to 12 months and
24 months. We decided to present the results of NEI-VFQ as it
was the relevant to review’s objective and because the results from
the SF-36 were reported separately for the mental and physical
components.
Adverse events
Both included studies reported on two key adverse events: the
number of participants receiving cataract surgery and the num-
ber of participants requiring intraocular pressure-lowering surgery.
Other adverse events reported by Kempen and colleagues were:
hyperlipidemia diagnosis requiring treatment (cumulative over 24
months), hypertension diagnosis requiring treatment (cumulative
through 24 months), diabetes mellitus (cumulative through 24
months), osteoporosis (cumulative through 24 months), white
blood cell count less than 2500/microliter (cumulative through 24
months), elevated liver enzymes (cumulative through 24 months),
cancer diagnosis through 24 months, and death through 24
months. The Pavesio study reported pooled non-ocular adverse
events through 24 months.
Excluded studies
After the full-text assessment, we excluded 45 studies (46 full-
text reports) (see Characteristics of excluded studies): six did not
focus on non-infectious posterior uveitis, intermediate uveitis,
or panuveitis; one did not have at least six months of follow-
up after treatment; 18 were not randomized controlled trials;
and 20 did not compare fluocinolone or dexamethasone im-
plant with standard-of-care therapy. No ongoing studies met the
review inclusion criteria (CTRI/2014/07/004726; CTRI/2014/
12/005337; NCT01694186; NCT02309385; NCT02482129;
NCT02517619).
Risk of bias in included studies
We have presented the ’Risk of bias’ assessment for the two in-
cluded studies in Figure 2.
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Figure 2. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
Allocation
We assessed both studies at a low risk of selection bias as they
reported adequate random sequence generation and concealment
of treatment allocation. Pavesio 2010 study used a voice response
system, while Kempen 2011 study used a website.
Masking (performance bias and detection bias)
The intervention group was surgically implanted steroid device,
and the comparison group was standard-of-care therapy. Both
studies were thus unable to mask participants and personnel to
which treatment groups each participant was in. We assessed both
studies at high risk of performance and detection bias for this rea-
son.
Incomplete outcome data
While “as-randomized” or “intention-to-treat” analyses were per-
formed in each study, we assessed the risk of bias as unclear, as there
was uncertainty whether the reasons participants did not complete
the final visit was associated with the review outcome; 6.4% of
participants did not complete the final visit in the Pavesio 2010
study, and 9% of participants did not complete the final visit in
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the Kempen 2011 study.
Selective reporting
The Kempen 2011 study was registered and all outcomes defined
in the trial registry was reported in the full-text reports. The
Pavesio 2010 study was not registered and the study protocol was
not available for comparison. Therefore, we assessed the risk of
reporting bias for Kempen 2011 study and the Pavesio 2010 study
to be at low and unclear risk of bias, respectively.
Other potential sources of bias
We assessed Pavesio 2010 to be at high risk of funding bias be-
cause several of the authors were employees of the sponsor, and the
lead author was a consultant for the sponsor. The authors did not
make any statement about the role of the sponsor in study design,
data analysis, interpretation, decision to publish, or manuscript
preparation. We assessed the Kempen 2011 study at unclear risk
of bias because the manufacturer of the steroid implant used pro-
vided support in the form of implants for participants who would
otherwise not have access to the implants due to lack of insurance
or regulatory approval in their country.
Effects of interventions
See: Summary of findings for the main comparison
Primary outcome
Recurrence of uveitis
None of the included studies reported the primary outcome at 6
months.Only one of two included studies reported on the primary
outcome at 24 months, therefore we did not perform a pooled
analysis and we report the study results as a narrative. Pavesio
2010 reported that the risk of recurrence of uveitis at any point
during the study through 24 months was 71% lower in the FA
implant group (23 of 61 eyes) compared with the standard-of-
care therapy group (48 of 71 eyes) (risk ratio (RR) 0.29, 95%
confidence interval (CI) 0.14 to 0.59). The study authors also
presented results of an alternative definition of recurrence, use of
systemic medication and number of medications participants with
FA implant received as part of incorrect or delayed tapering of
uveitis medications, and showed a greater reduction (87%) in the
risk of recurrence of uveitis in the FA implant group (12 of 61
eyes) compared with the standard-of-care therapy group (47 of 71
eyes) (RR 0.13, 95% CI 0.06 to 0.28). We judged the quality of
the evidence for this outcome to be moderate, downgraded for
high risks of bias in the study (-1).
Secondary outcomes
Best-corrected visual acuity (BCVA)
Only the Kempen study reported on the change in BCVA as mea-
sured by logMAR chart. The authors did not report the number
of participants analyzed in the FA implant group and standard-
of-care therapy group, but they did report the between-group es-
timates. The Kempen study was powered to detect a difference of
7.5 letters (standard deviation (SD) = 16) with a power of 91%
and sample size of 250 participants.
At 12 months, there was an improvement from baseline of 4.61
(SD = 1.38) letters in the FA implant group, compared with 3.33
(SD = 1.23) letters in the standard-of-care therapy group (Table 1
mean difference (MD) 1.29 letters, 95%CI -2.32 to 5.01; positive
value favoring implant; 437 eyes). It is uncertain whether FA im-
plant increases the number of letters read compared with the stan-
dard-of-care therapy group, and the differences in improvement
were at or below the threshold of minimally important differences
detected by this instrument.
At 24 months, there was an improvement from baseline of 6.03
(SD = 1.41) letters in the FA implant group, compared with 3.23
(SD = 1.41) letters in the standard-of-care therapy group (Table
1 MD 2.79 letters, 95% CI -1.16 to 6.88; positive value favoring
implant; 435 eyes). It is uncertain whether FA implant increases
the number of letters read compared with the standard-of-care
therapy group, and the differences in improvement were at or
below the threshold of minimally important differences detected
by this instrument.
We judged the quality of the evidence for visual acuity outcomes
to be moderate, downgraded for high risks of bias in the study (-
1).
Mean change in quality of life
Only the Kempen study reported on the mean change in quality
of life. The study reported the between-group estimates and did
not report the number of participants analyzed in each group.
At 12 months, the mean change from baseline NEI-VFQ for the
FA implant group was 12.13 (SD = 1.60) compared with the stan-
dard-of-care therapy group, which was 4.86 (SD = 1.38) (Table 1
MD 7.29, 95% CI 3.11 to 11.42; positive value favoring implant;
235 eyes). The differences in change in NEI-VFQ were at or be-
low the threshold of minimally important differences detected by
this instrument.
At 24 months, the mean change from baseline NEI-VFQ for the
FA implant group was 11.44 (SD = 1.67) compared with the
standard-of-care therapy group,whichwas 6.80 (SD=1.58) (Table
1MD 4.64, 95%CI 0.14 to 9.15; positive value favoring implant;
232 eyes). The differences in change inNEI-VFQwere at or below
the threshold of minimally important differences detected by this
instrument.
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We judged the quality of the evidence for quality of life outcomes
to be moderate, downgraded for high risks of bias in the study (-
1).
Both studies did not report on the following secondary outcomes:
mean change in cystoid macular edema and the proportion of par-
ticipants that required additional therapeutic modalities to control
inflammation.
Adverse events
Both studies reported adverse events, and we performed a pooled
analysis.Wehave presented two important adverse events in Figure
3 and Figure 4. Both included studies only reported cumulative
adverse events through 24 months’ follow-up.
Figure 3. Forest plot of comparison: 1 Fluocinolone implant versus standard of care, outcome: 1.2 Cataract
surgery through 24 months.
Figure 4. Forest plot of comparison: 1 Fluocinolone implant versus standard of care, outcome: 1.6 IOP-
lowering surgery performed through 24 months.
Cataract formation or progression
Moderate-quality evidence showed that the risk of cataracts form-
ing or progressing within two years in the FA implant group was
about three times the risk compared with standard-of-care therapy
(Analysis 1.1; RR 2.71, 95%CI 2.06 to 3.56; 210 eyes; I2 = 80%).
We did not downgrade for risk of performance and detection bias
because the outcome measurement was not likely to be influenced
by lack of masking. We downgraded for high risk of funding bias
(-1).
Cataract surgery
Moderate-quality evidence showed that the risk of receiving
cataract surgery within two years in the FA implant group was
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about three times the risk compared with standard-of-care therapy
(Analysis 1.2; RR 2.98, 95%CI 2.33 to 3.79; 371 eyes; I2 = 70%).
We did not downgrade for risk of performance and detection bias
because the outcome measurement was not likely to be influenced
by lack of masking. We downgraded for high risk of funding bias
(-1).
Elevated intraocular pressure > 10 mmHg over baseline or
receiving intervention (eye drops or surgery)
Moderate-quality evidence showed that the risk of elevated in-
traocular pressure > 10 mmHg over baseline or receiving inter-
vention (eye drops or surgery) in the FA implant group was more
than 3 times the risk with standard-of-care therapy (Analysis 1.3;
RR 3.64, 95% CI 2.71 to 4.87; 605 eyes; I2 = 25%). We did not
downgrade for risk of performance and detection bias because the
outcome measurement was not likely to be influenced by lack of
masking. We downgraded for high risk of funding bias (-1).
Endophthalmitis
While there were more cases of endophthalmitis in the FA im-
plant group in the Pavesio report, the very low quality evidence
show that it is uncertain whether FA implant increased the risk of
endophthalmitis (Analysis 1.4; RR 7.30, 95% CI 0.91 to 58.72;
607 eyes; I2 = 0%). We downgraded for high risk of bias (-1), high
risk of funding bias (-1), and imprecision of results (-1).
Retinal tear or retinal detachment
The very low quality evidence shows that it is uncertain whether
FA implant causes retinal tears or retinal detachment (Analysis
1.5; RR 2.07, 95% CI 0.51 to 8.40; 606 eyes; I2 = 44%). We
downgraded for high risk of bias (-1), high risk of funding bias (-
1), and imprecision of results (-1).
Intraocular pressure-lowering surgery
Moderate-quality evidence showed that the risk of requiring in-
traocular pressure-lowering surgery within two years in the FA im-
plant group was seven times the risk with standard-of-care therapy
(Analysis 1.6; RR 7.48, 95%CI 3.94 to 14.19; 599 eyes; I2 = 0%).
We did not downgrade for risk of performance and detection bias
because the outcome measurement was not likely to be influenced
by lack of masking. We downgraded for high risk of funding bias
(-1).
Hypotony
The risk of hypotony through two years’ follow-up in the FA
implant group was twice the risk with standard-of-care therapy
(Analysis 1.7; RR 2.27, 95%CI 1.24 to 4.14; 586 eyes; I2 = 81%).
The quality of the evidence was very low, downgraded for high
risk of bias of performance and detection bias (-1), high risk of
funding bias (-1), and imprecision of results (-1).
Systemic adverse events related to steroid or
immunomodulatory therapy
The two studies reported non-ocular adverse events differently,
and thus we could not pool the data. Pavesio 2010 reported that
the risk of adverse event was similar in the FA implant (60.6%)
compared with the standard-of-care therapy group (67.6%), al-
though none of the events reported in the FA implant group were
deemed to be related to the treatment assignment, as compared
with 25.7% of the events that were felt to be related to treatment
in the standard-of-care therapy group. Kempen 2011 reported
the rate of infection requiring prescription therapy to be lower in
the FA implant group compared with the standard-of-care ther-
apy group (0.36 versus 0.60 events per person-year, respectively;
P = 0.034), but found the rate of hospitalizations did not differ
(0.13 versus 0.17 hospitalizations per person-year, respectively; P
= 0.35). The risk of hypertension was lower in the FA implant
group compared with standard-of-care therapy group (13% versus
27%, respectively; hazard ratio = 0.44, P = 0.030), but the rate of
starting antihypertensive therapy did not differ (5% versus 11%;
hazard ratio = 0.40, P = 0.13).
D I S C U S S I O N
Summary of main results
After considering both benefits and harms reported from two ran-
domized trials in which corticosteroid implants were compared
with standard-of-care therapy in 401 participants with mean age
approximately 40 years, we are unable to conclude that the im-
plants are superior to traditional systemic therapy for the treat-
ment of non-infectious uveitis (Summary of findings for the main
comparison). Each study individually concluded that corticos-
teroid implants can be considered a reasonable alternative to stan-
dard-of-care therapy, but the pooled data do not support (or re-
fute) their conclusion. Pavesio 2010 was an industry-sponsored
study that included participants whose uveitis was required to be
inactive at the time of study entry. Their outcome of interest was
therefore recurrence of uveitis signs or symptoms. The Kempen
2011 study was a National Eye Institute-sponsored randomized
controlled trial of people with active uveitis in which the primary
outcome was the change in BCVA. Due to heterogeneity in the
design of the studies and outcome measures assessed, we could
not combine the results for the primary and secondary outcomes
of this review. As a result, the evidence for or against the use of
corticosteroid implants in the treatment of non-infectious uveitis
is limited.
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Since the safety endpoints were similar in the two studies, we
pooled the data for these adverse events (Analysis 1.1 to Analysis
1.7). These analyses concluded that cataract formation/progres-
sion, cataract surgery, elevated intraocular pressure, intraocular
pressure-lowering surgery, hypotony, retinal detachment, and en-
dophthalmitis were more common in the FA implant group than
the standard-of-care therapy group. While this result is not unex-
pected, clinicians may cautiously find some value in the updated
risk ratios for each adverse event afforded by the pooled analysis.
Reasons for excluding several studies of corticosteroid implants
for uveitis from the review are described in the Characteristics of
excluded studies table. We excluded many studies because they
were not randomized controlled trials or did not compare corticos-
teroid implants with standard-of-care therapy.Most notably, none
of the studies of the dexamethasone intravitreal implant met our
inclusion/exclusion criteria. The principal report from these stud-
ies, Lowder 2011b, compared the dexamethasone implant with
sham injection, not to standard-of-care therapy, which was an in-
clusion criterion for our review.
Overall completeness and applicability of
evidence
The two studies included in our review investigated the compara-
tive effectiveness of FA implants against standard-of-care therapy.
We found no conclusive evidence showing whether FA implants is
superior to standard-of-care therapy in preventing the recurrence
of uveitis. We evaluated no other steroid implants. The two in-
cluded studies did not distinguish between posterior uveitis, panu-
veitis, and intermediate uveitis. The applicability to a non-Euro-
pean and minority population in the United States is limited.
Quality of the evidence
We downgraded outcomes in this review due to funding bias,
imprecision of results, and high risk of bias in individual studies.
Specifically, we assessed both studies at high risk of performance
and detection bias. The nature of the study question (comparing
a steroid implant with systemically administered medications) is
certainly problematic from a masking perspective.
Potential biases in the review process
We used standard Cochrane methodological procedures in order
to minimize potential biases in the review process. We reported
all outcomes that were specified in the protocol for this review or
reported that no data were available for specified outcomes.
Agreements and disagreements with other
studies or reviews
Our search identified several review articles discussing the use of
corticosteroid implants in the treatment of non-infectious poste-
rior uveitis, but we did not find any other systematic reviews with
which to compare our results.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
In the absence of any substantial newly synthesized evidence for
or against the use of corticosteroid implants for non-infectious
uveitis, we are unable to conclude that the implants are superior
to standard-of-care therapy for the treatment of non-infectious
uveitis. These studies exhibit heterogeneity in design and out-
comes measured. Taken together, clinicians and patients will need
to anticipate the possibility of an increased risk of post-implant
surgery for cataract and high intraocular pressure.
Implications for research
The paucity of data this review identified using the prespecified in-
clusion/exclusion criteria, and our inability to performpooled effi-
cacy analyses indicate that there is a distinct need for further stud-
ies of corticosteroid implants for non-infectious posterior uveitis.
Researchers may want to devise research questions that allow for
incorporation of study design elements frompreviously conducted
studies to better permit pooled analyses/meta-analyses, such as:
• better measures that are standardized (e.g. recurrence of
uveitis);
• homogenous comparators (comparing fluocinolone
acetonide or dexamethasone intravitreous implants with
standard-of-care therapy);
• extending to various types of uveitis (e.g. chronic posterior
uveitis, intermediate uveitis, panuveitis); and
• standardizing standard-of-care therapy (e.g. systemic
steroids, intravitreal steroids, disease-modifying antirheumatic
drugs) given the heterogeneity of individual therapies,
combination regimens and their attendant adverse event profiles.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Kempen 2011
Methods Study design: parallel-group, randomized controlled trial
Number randomized:
Total: 255 participants (479 eyes)
FA implant group: 129 participants (245 eyes)
Standard-of-care group: 126 participants (234 eyes)
Number analyzed:
Total: 255 participants (479 eyes)
FA implant group: 129 participants (245 eyes)
Standard-of-care group: 126 participants (234 eyes)
Exclusions and loss to follow-up:
Total: 23 participants
FA implant group: 11 participants
Standard-of-care group: 12 participants
Study follow-up: 24 months
Participants Country: Australia, United Kingdom, United States
Age (mean ± SD, range): 46.3 ± 15.0, 34 to 56 years
Gender:
Overall:
Women: 192/255 participants (75%)
Men: 63/255 participants (25%)
By group: not reported
Inclusion criteria:
“1. Age 13 years or older
2. Diagnosis of noninfectious intermediate uveitis, posterior uveitis, or panuveitis by a
MUST-certified ophthalmologist
3. Active uveitis of a degree for which systemic corticosteroid therapy is indicated in the
judgment of a MUST-certified ophthalmologist or such uveitis active within the last 60
days as determined either by examination by a MUST-certified ophthalmologist or by
review of ophthalmic medical records by a MUST-certified ophthalmologist
4. Uveitis with or without an associated systemic disease is acceptable; however, the sys-
temic disease must not be sufficiently active that it dictates therapy with oral corticos-
teroids or immunosuppressive agents at the time of study entry
5. Best-corrected visual acuity of hand movements or better in at least 1 eye with uveitis
6. Baseline intraocular pressure of 24 mm Hg or less in all eyes with uveitis
7. Collection of required baseline data within 10 days before randomization
8. Signed informed consent”
Exclusion criteria:
“1. Use of a fluocinolone acetonide implant within the last 3 years
2. Diabetes mellitus that is inadequately controlled, according to best medical judgment
3. A known allergy to a required study medication
4. Uncontrolled glaucoma
5. Advanced glaucomatous optic nerve injury meeting the following criteria: (1) for
patients able to undertake a Humphrey visual field analysis, depression of 2 points or
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Kempen 2011 (Continued)
more within 10 degrees of fixation by at least 10 dB, mean deviation worse than -15 dB,
or both; (2) for patients unable to undertake a Humphrey visual field analysis, vertical
cup-to-disc ratio [1]0.9
6. A history of scleritis (because of concerns regarding the potential for scleral melting
with local corticosteroid therapy)
7. Presence of an ocular toxoplasmosis scar
8. Pregnancy
9. Current breastfeeding
10. Knownhuman immunodeficiency virus infection or other immunodeficiency disease
for which corticosteroid therapy would be contraindicated according to best medical
judgment
11. Patients for whom participation in the trial would constitute a risk exceeding the
potential benefits of study participation, in the judgment of the treating physician
12. Medical problems or drug or alcohol dependence problems sufficient to prevent
adherence to treatment and study procedures”
Participants with unilateral and asymmetric bilateral disease were included:
For participantswith unilateral disease, the affected eyewas the study eye. For participants
with asymmetric bilateral disease, both eyes were study eyes
Interventions FA implant: surgical FA implant (0.59 mg) placement
Standard-of-care: “systemic therapy following expert guidelines”
“Most cases had active inflammation at baseline and received 1 mg/kg/day up to 60
mg/day of prednisone until either the uveitis was controlled or 4 weeks had elapsed.
After control was achieved, prednisone was tapered per study guidelines. Cases already
suppressed at baseline began by tapering from their initial prednisone dose. Immuno-
suppression was indicated for (1) failure to initially control inflammation using corti-
costeroids; (2) corticosteroid-sparing in cases consistently reactivating before reaching
a prednisone dose of 10 mg/day; and (3) specific high-risk uveitis syndromes. When
indicated, clinicians selected the approved immunosuppressant most suitable for each
patient; administration and monitoring for toxicity followed guidelines.8 Uveitis experts
regularly monitored treatment regimens for protocol compliance at site visits.” P1917
General procedures: ophthalmologic examination
Outcomes Primary outcome: change in best-corrected visual acuity from baseline
Secondary outcome(s): patient-reported quality of life, ophthalmologist-graded uveitis
activity, and local and systemic complications of uveitis or therapy
Other outcomes(s): hyperlipidemia diagnosis requiring treatment, cumulative over 24
months, hypertension diagnosis requiring treatment, cumulative through 24 months,
diabetes mellitus, cumulative through 24 months, osteoporosis, cumulative through
24 months, white blood cell count < 2500/microliter, cumulative through 24 months,
elevated liver enzymes, cumulative through 24 months, elevated creatinine, cumulative
through 24 months, cancer diagnosis through 24 months, death through 24 months
Measurements taken: outcomes assessed at 1 month after enrollment, 3 months after
enrollment, and then at 3-month intervals until 24 months
Unit of analysis: mix of individuals and eyes (one eye of 31 participants (12%) and
both eyes of 224 participants (88%), respectively, were study eyes)
Sample size calculation: “By assuming bilateral disease in 67%of patients, a between eye
correlation of 0.4, a standard deviationof 16 letters’ change over 2 years, and a 2-sided type
1 error rate of 0.05, a sample size of 250 provided 91% power (assuming 10% crossover)
23Corticosteroid implants for chronic non-infectious uveitis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Kempen 2011 (Continued)
to detect a treatment difference of 7.5 standard Early Treatment of Diabetic Retinopathy
Study letters’ change in visual acuity from baseline to 24 months, a difference similar
to that which drove widespread use of expensive new retinal treatments in other trials
that tested them. One interim analysis using the O’Brien-Fleming-spending function
was conducted; the nominal type 1 error rate was 0.049 for the final analysis.”
Notes Study dates: December 2005 to December 2008
Funding sources:National Eye Institute, Research to Prevent Blindness, Paul and Evan-
ina Mackall Foundation. Bausch and Lomb provided “support to the study in the form
of a donation of a limited number of fluocinolone implants to patients who were …
uninsured or otherwise unable to pay for the implants”
Declaration of interest:
“Dr Kempen is a consultant for Alcon Laboratories, Allergan Pharmaceutical Corpora-
tion, Lux Biosciences Inc, and Sanofi Pasteur SA. Dr Jabs is a consultant for Abbott Lab-
oratories, Alcon Laboratories, Allergan Pharmaceutical Corporation, Corcept Therapeu-
tics, Genentech Inc, Genzyme Corporation, GlaxoSmithKline, Novartis Pharmaceutical
Corporation, Roche Pharmaceuticals, and Applied Genetic Technologies Corporation.
Dr Louis is a consultant for Bristol-Myers Squibb, Medtronic Inc, and the National
Institute of Diabetes and Digestive and Kidney Diseases. Dr Thorne is a consultant for
Heron Evidence Ltd, and Allergan. Drs Altaweel, Holbrook, and Sugar have no conflicts
of interest.”
Trial registry: NCT00132691 (clinicaltrials.gov)
Publication language: English
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Patients were randomized to implant or
systemic therapy; patients with bilateral
uveitis were assigned to receive implants
in each eye meeting eligibility criteria.
Randomization (1:1 ratio) was by variable
length, permuted blocks within 2 strata
(clinical center, intermediate vs posterior
or panuveitis), with assignments produced
by Stata 11.0 (StataCorp 2009, Stata Sta-
tistical Software: Release 11; StataCorp LP,
College Station, TX).” P1917
Allocation concealment (selection bias) Low risk “After data entry confirmed a subject’s el-
igibility and stratum, the study Web site
revealed the next treatment assignment.”
P1917
Masking of participants and personnel
(performance bias)
High risk “Study-certified visual acuity examiners
measured best-corrected visual acuity as the
number of letters read from standard log-
arithmic visual acuity charts; 14 change in
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this measure from baseline to 24 months
was the primary outcome.” P1917
“Other than at the 1- and 3-month vis-
its, when postoperative signs were expected
to be visible, visual acuity examiners were
masked.” P1917
“Secondary outcomes included patient-re-
ported quality of life, ophthalmologist-
graded uveitis activity, and local and sys-
temic complications of uveitis or ther-
apy. Reading Center graders and glaucoma
specialists assessing ocular complications
were masked. Participants, ophthalmolo-
gists, and coordinators were unmasked.”
P1916
Masking of outcome assessment (detection
bias)
High risk “Study-certified visual acuity examiners
measured best-corrected visual acuity as the
number of letters read from standard log-
arithmic visual acuity charts; 14 change in
this measure from baseline to 24 months
was the primary outcome.” P1917
“Other than at the 1- and 3-month vis-
its, when postoperative signs were expected
to be visible, visual acuity examiners were
masked.” P1917
“Secondary outcomes included patient-re-
ported quality of life, ophthalmologist-
graded uveitis activity, and local and sys-
temic complications of uveitis or ther-
apy. Reading Center graders and glaucoma
specialists assessing ocular complications
were masked. Participants, ophthalmolo-
gists, and coordinators were unmasked.”
P1916
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk “Among patients randomized, 232 (435
eyes with uveitis; 91%) completed vi-
sual acuity measurement at the 24-month
follow-up visit. Overall, 4415 of 4790
study visits (92%) were completed for the
primary outcome through 24 months.”
P1919
“Analyses were conducted ’as randomized.
’” P1918
Selective reporting (reporting bias) Low risk All outcomes defined in trial registry were
reported.
25Corticosteroid implants for chronic non-infectious uveitis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Kempen 2011 (Continued)
Other bias Unclear risk The study was federally funded, although
the device manufacturer “Bausch & Lomb
provided support to the study in the formof
donation of fluocinolone implants for pa-
tients randomized to implant therapy who
were uninsured or otherwise unable to pay
for implants, or were located at a site where
implants could not be purchased (e.g., in
the United Kingdom).” P1926
“A representative of the National Eye In-
stitute participated in the conduct of the
study, including the study design and the
collection, management, analysis, and in-
terpretation of the data, and in the review
and approval of this manuscript.” P1926
Pavesio 2010
Methods Study design: parallel-group, randomized controlled trial
Number randomized:
Total: 146 participants
FA implant group: 72 participants
Standard-of-care group: 74 participants
Number analyzed at 24 months’ follow-up:
Total: 140 participants
FA implant group: 66 participants
Standard-of-care group: 74 participants
Exclusions and loss to follow-up: 6 treatment group participants excluded due to
administrative problems (3), consent withdrawal (2), adverse events (1)
Study follow-up: 24 months
Participants Countries: France, Germany, Israel, Italy, Portugal, Saudi Arabia, Spain, Switzerland,
Turkey, United Kingdom
Age (mean ± SD, range):
Overall: not reported
FA implant group: 40.4 ± 14.4 years, 12 to 75 years
Standard-of-care group: 43.1 ± 13.5 years, 18 to 70 years
Gender:
Overall:
Women: 85/146 participants (58.2%);
Men: 61/146 participants (41.8%)
FA implant group:
Women: 35/72 participants (48.5%);
Men: 37/72 participants (51.5%)
Standard-of-care group:
Women: 50/74 participants (67.6%)
Men: 24/74 participants (32.4%)
Inclusion criteria: [if this is copied text, need quotes]
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• “Quiet eyes at the time of treatment. Only eye randomized to implant had to be
quiet at the time of surgery. Treatment with either ≥ 0.2 mg/kg daily prednisolone
equivalent or ≥ 0.1 mg/kg daily prednisolone equivalent immunosuppressant at the
time of randomization was required.
• Male or non-pregnant female aged ≥ 6 years
• ≥ 1-year history of recurrent or recrudescent unilateral or asymmetric NIPU not
associated with significant systemic activity of any underlying disease
• More severely affected eyes with ≥ 2 separate recurrences of NIPU and the last
episode occurring within 8 months of enrolment
• More severely affected eyes were treated with systemic therapy for ≥ 1 month: ≥
0.2 mg/kg daily prednisolone equivalent (≥ 10 mg/kg daily for participants > 50 kg) or
≥ 0.1 mg/kg daily prednisolone equivalent if steroids were given with ½ of the
following immunosuppressive agents:
◦ cyclosporine A, methotrexate
◦ cyclophosphamide, tacrolimus
◦ mycophenolate mofetil, azathioprine
• Less severely affected eyes with:
◦ VA of ≥ 0.7 logMAR (6/30)
◦ Uveitis requiring only periocular injections or no therapy
• Study eyes at time of enrolment:
◦ VA of ≥ 1.4 logMAR (6/150)
◦ ≤ 10 anterior chamber cells/high-power field and a vitreous haze grade ≤ 2”
Exclusion criteria: [if this is copied text, need quotes]
• “History of retinal detachment, retinoschisis in the area of implantation
• Media opacity precluding evaluation of the retina and vitreous
• Presence or history of uncontrolled IOP while receiving steroid therapy resulting
in loss of vision
• IOP > 25 mmHg requiring at least 2 antiglaucoma medications to be reduced to
< 25 mmHg
• Known allergy or contraindication to fluocinolone acetonide, systemic
corticosteroids, or immunosuppressive agents
◦ Chronic use of such agents to manage nonocular disease
• History of NIPU only or iritis only with no vitreitis, macular edema, vitreous
cells, or vitreous haze
• Infectious cause
• Vitreous haemorrhage or a toxoplasma scar in the study eye
• Ocular surgery, trauma affecting the study eye, or both within 3 months before
enrolment, or trabeculoplasty or yttrium-aluminum-garnet laser within 1 month of
enrolment
• Monocularity for reasons other than uveitis
• Positive human immunodeficiency virus test results, pregnancy or lactation
• Potential for noncompliance, or participation in other clinical studies within 1
month of enrolment”
Participants with unilateral and asymmetric bilateral disease were included:
For participantswith unilateral disease, the affected eyewas the study eye. For participants
with asymmetric bilateral disease, the study eye was the more severely affected eye
Interventions FA implant: surgical implantation of 0.59 mg FA in vitreous cavity
Standard-of-care: standard-of-care systemic management of uveitis
27Corticosteroid implants for chronic non-infectious uveitis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Pavesio 2010 (Continued)
“The SOC group received prednisolone or an equivalent corticosteroid alone, or an
immunosuppressive agent was added to the therapy and the corticosteroid dose was re-
duced. Levels considered acceptable for therapy with steroids alone were 0.2 mg/kg daily
(or 15 mg/day for the average weight). When inflammation could not be controlled
with this level of corticosteroid, immunosuppressive agents were added. With the use
of an immunosuppressive agent, the objective was to reduce steroid use to 0.1 mg/kg
daily of prednisolone equivalent after 4 to 6 weeks of combination therapy. Approved
immunosuppressants included cyclosporine A, methotrexate, cyclophosphamide, my-
cophenolate mofetil, azathioprine, and tacrolimus. If an immunosuppressive agent was
not recommended, subjects were managed by maintaining systemic steroids at a higher
level (0.2 mg/kg daily of prednisolone equivalent) or by increasing the steroids in case of
inflammation. This regimen was followed by a slow taper to a minimal dose of 0.2 mg/
kg daily (10 mg/day for subjects whose weight was 50 kg). After 6 months, if the disease
was controlled, the treatment doses were tapered according to the standard guideline of
each investigational site.” P569
General procedures: ophthalmic examination
Outcomes Primary outcomes: time to first recurrence of uveitis occurring in the 24 months after
randomization for the standard-of-care group and time to first recurrence of uveitis in
the study eye in the 24 months after the week 12 visit for the implant group
Secondary outcomes:
• Percentage of participants with at least 1 recurrence
• Number of recurrences per participant
• Number of recurrences compared with the number that occurred during the 52
weeks before enrollment
• Proportion of participants with a VA improvement (> 15 letters on Early
Treatment Diabetic Retinopathy Study charts from baseline)
• If cystoid macular edema present, the change in the size of the area of cystoid
macular edema on fluorescein angiography
Measurements taken, specify intervals at which outcomes assessed: Participants were
assessed monthly for 3 months, bimonthly for 6 months, and then every 3 months for
the second year of the study
Unit of analysis: individual (one eye per participant)
Sample size calculation: “A sample size of 75 subjects per treatment was determined
to have 85% power to detect a difference with respect to the primary end point in a 2-
tailed test (0.05).”
Notes Study dates: April 2002 through August 2005
Funding source: Bausch and Lomb Inc
Declaration of interest: Of the 5 study authors, lead author is a consult for Bausch and
Lomb Inc, and 3 authors are employees of Bausch and Lomb Inc
Trial registry: not registered
Publication language: English
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Low risk “Subjects were allocated to receive either an
implant or standardized therapy as deter-
mined by a randomization code with treat-
ment randomizationnumbers assignedby a
centrally administered randomization pro-
cedure.” P569
Allocation concealment (selection bias) Low risk “Treatment allocation was masked to both
the investigator and the subject through the
use of an interactive voice response system
that informed the investigator of the treat-
ment group only after confirmation of in-
clusion of the subject.” P569
Masking of participants and personnel
(performance bias)
High risk The study was designed to assess surgical
implant vs standard-of-care oral therapy. “.
.. it was not possible to mask study treat-
ments ...” P569
Masking of outcome assessment (detection
bias)
High risk Nomasking for primary outcomes. For sec-
ondary outcomes: “... some assessments,
including fluorescein angiography, fundus
photography, and laboratory parameters,
were masked.” P569
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk “Six subjects randomized to the FA implant
group discontinued before receiving treat-
ment because of administrative problems,
consent withdrawal, or AEs and were ex-
cluded from the intent-to-treat population.
” P570. Data for all other participants was
included
“All randomized subjectswhounderwent at
least 1 assessment after randomization were
included in the intent-to-treat population,
and all efficacy and safety summaries were
based on the intent-to-treat populations.
Data from the per-protocol population also
were analyzed for most outcome measures.
” P570
Selective reporting (reporting bias) Unclear risk Study protocol and trial registry were not
available for comparison. All of the prespec-
ified outcomes from the methods section
were reported in the results section
Other bias High risk Several of the authors are employees of the
sponsor, and the lead author is a consul-
tant for the sponsor. There is no statement
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about the role of the sponsor in study de-
sign, data analysis, interpretation, decision
to publish, or manuscript preparation
AE: adverse event
FA: fluocinolone acetonide
IOP: intraocular pressure
MUST: Multicenter Uveitis Steroid Treatment
N/A: not applicable
NIPU: non-infectious posterior uveitis
SD: standard deviation
VA: visual acuity
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Acharya 2004 Not a RCT.
Anonymous 1995 Wrong type of participants were included; did not assess non-infectious posterior uveitis, intermediate
uveitis, or panuveitis
Ansari 2010 Not a RCT.
Arcinue 2013 Not a RCT.
Bollinger 2009 Wrong type of participants were included; did not assess non-infectious posterior uveitis, intermediate
uveitis, or panuveitis
Callanan 2008a Did not compare fluocinolone or dexamethasone implant with standard-of-therapy. The study compared
0.59-mg FA intravitreal implant with 2.1-mg FA intravitreal implant
Campochiaro 2013 Wrong type of participants were included; did not assess non-infectious posterior uveitis, intermediate
uveitis, or panuveitis
Cano-Parra 2006 Not a RCT.
CTRI/2014/07/004726 Did not compare fluocinolone or dexamethasone implant with standard-of-therapy. The study compared
FA intravitreal implant with sham injection
CTRI/2014/12/005337 Did not compare fluocinolone or dexamethasone implant with standard-of-therapy. The study compared
FA intravitreal implant with sham injection
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Eng 2007 Wrong type of participants were included; did not assess non-infectious posterior uveitis, intermediate
uveitis, or panuveitis
Ermakova 2003 Not a RCT.
Galor 2007 Not a RCT.
Garg 2006 Not a RCT.
Goldstein 2007 Did not compare fluocinolone or dexamethasone implant with standard-of-therapy. The study compared
0.59-mg FA intravitreal implant with 2.1-mg FA intravitreal implant
Ibrahim 2009 Not a RCT.
Jaffe 2000a Not a RCT.
Jaffe 2000b Not a RCT.
Jaffe 2005a Did not compare fluocinolone or dexamethasone implant with standard-of-therapy. The study compared
0.59-mg FA intravitreal implant with 2.1-mg FA intravitreal implant
Jaffe 2005b Not a RCT.
Jaffe 2006a Did not compare fluocinolone or dexamethasone implant with standard-of-therapy. The study compared
0.59-mg FA intravitreal implant with 2.1-mg FA intravitreal implant
Jaffe 2006b Did not compare fluocinolone or dexamethasone implant with standard-of-therapy.The study compared
0.59-mg FA intravitreal implant with 2.1-mg FA intravitreal implant
Kim 2011 Not a RCT.
Kuppermann 2007 Wrong type of participants were included; did not assess non-infectious posterior uveitis, intermediate
uveitis, or panuveitis
Lowder 2011a Did not compare fluocinolone or dexamethasone implant with standard-of-therapy. Participants were
randomized to either a sham procedure or treatment with the 0.7-mg or 0.35-mg DEX implant
Mercante 2007 Did not compare fluocinolone or dexamethasone implant with standard-of-therapy. The study compared
0.59-mg FA intravitreal implant with 2.1-mg FA intravitreal implant
Muller 2004 Did not compare fluocinolone or dexamethasone implant with standard-of-care therapy. The study com-
pared 0.59-mg FA intravitreal implant with 2.1-mg FA intravitreal implant
Mustakallio 1973 Wrong type of participants were included; did not assess non-infectious posterior uveitis, intermediate
uveitis, or panuveitis
Naik 2013 Did not compare fluocinolone or dexamethasone implant with standard-of-care therapy. The study com-
pared dexamethasone intravitreal implant with sham injection
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NCT01694186 Did not compare fluocinolone or dexamethasone implant with standard-of-therapy.The study compared
FA intravitreal implant with sham injection
NCT02309385 Did not have at least six months of follow-up after treatment
NCT02482129 Did not compare fluocinolone or dexamethasone implant with standard-of-care therapy. The study com-
pared LME636 60 mg/mL ophthalmic solution with dexamethasone 0.1% ophthalmic solution
NCT02517619 Did not compare fluocinolone or dexamethasone implant with standard-of-care therapy. The study com-
pared dexamethasone ophthalmic solution (40 mg/mL) with prednisolone acetate ophthalmic solution
(1%)
Neger 1996 Wrong type of participants were included; did not assess non-infectious posterior uveitis, intermediate
uveitis, or panuveitis
Novack 2008 Not a RCT.
Ram 2013 Wrong type of participants were included; did not assess non-infectious posterior uveitis, intermediate
uveitis, or panuveitis
Sangwan 2007 Did not compare fluocinolone or dexamethasone implant with standard-of-care therapy. The study com-
pared 0.59-mg FA intravitreal implant with 2.1-mg FA intravitreal implant
Saraiya 2011 Not a RCT.
Sheppard 2012 Did not compare fluocinolone or dexamethasone implant with standard-of-care therapy. The study com-
pared 0.59-mg FA intravitreal implant with 2.1-mg FA intravitreal implant
Taylor 2012 Not a RCT.
Viola 2009 Not a RCT.
Wen 1991 Did not compare fluocinolone or dexamethasone implant with standard-of-therapy. The study compared
Chinese traditional dialectic therapy combined with eastern medicine versus western medicine
Williams 2004 Did not compare fluocinolone or dexamethasone implant with standard-of-care therapy and included
participants with either uveitis or Irvine-Gass syndrome
Williams 2009 Did not compare fluocinolone or dexamethasone implant with standard-of-care therapy. Participants were
randomized to 350- g dexamethasone or 700- g dexamethasone or observation
Yeh 2008 Not a RCT.
FA: fluocinolone acetonide
mg: milligram
RCT: randomized controlled trial
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D A T A A N D A N A L Y S E S
Comparison 1. Fluocinolone implant versus standard-of-care
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Cataract formation or
progression through 24 months
2 210 Risk Ratio (M-H, Fixed, 95% CI) 2.71 [2.06, 3.56]
2 Cataract surgery through 24
months
2 371 Risk Ratio (M-H, Fixed, 95% CI) 2.98 [2.33, 3.79]
3 Elevated intraocular pressure >
10 mmHg cumulative through
24 months
2 605 Risk Ratio (M-H, Fixed, 95% CI) 3.64 [2.71, 4.87]
4 Endophthalmitis through 24
months
2 607 Risk Ratio (M-H, Fixed, 95% CI) 7.30 [0.91, 58.72]
5 Retinal detachment through 24
months
2 606 Risk Ratio (M-H, Fixed, 95% CI) 2.07 [0.51, 8.40]
6 IOP-lowering surgery performed
through 24 months
2 599 Risk Ratio (M-H, Fixed, 95% CI) 7.48 [3.94, 14.19]
7 Hypotony through 24 months 2 586 Risk Ratio (M-H, Fixed, 95% CI) 2.27 [1.24, 4.14]
Analysis 1.1. Comparison 1 Fluocinolone implant versus standard-of-care, Outcome 1 Cataract formation
or progression through 24 months.
Review: Corticosteroid implants for chronic non-infectious uveitis
Comparison: 1 Fluocinolone implant versus standard-of-care
Outcome: 1 Cataract formation or progression through 24 months
Study or subgroup Fluocinolone implant Standard of care Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Kempen 2011 49/54 22/50 65.5 % 2.06 [ 1.49, 2.85 ]
Pavesio 2010 44/49 13/57 34.5 % 3.94 [ 2.42, 6.41 ]
Total (95% CI) 103 107 100.0 % 2.71 [ 2.06, 3.56 ]
Total events: 93 (Fluocinolone implant), 35 (Standard of care)
Heterogeneity: Chi2 = 4.99, df = 1 (P = 0.03); I2 =80%
Test for overall effect: Z = 7.12 (P < 0.00001)
Test for subgroup differences: Not applicable
0.2 0.5 1 2 5
Favors fluocinolone Favors standard of care
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Analysis 1.2. Comparison 1 Fluocinolone implant versus standard-of-care, Outcome 2 Cataract surgery
through 24 months.
Review: Corticosteroid implants for chronic non-infectious uveitis
Comparison: 1 Fluocinolone implant versus standard-of-care
Outcome: 2 Cataract surgery through 24 months
Study or subgroup Fluocinolone Standard of care Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Kempen 2011 113/140 39/125 80.2 % 2.59 [ 1.97, 3.40 ]
Pavesio 2010 43/49 11/57 19.8 % 4.55 [ 2.65, 7.81 ]
Total (95% CI) 189 182 100.0 % 2.98 [ 2.33, 3.79 ]
Total events: 156 (Fluocinolone), 50 (Standard of care)
Heterogeneity: Chi2 = 3.37, df = 1 (P = 0.07); I2 =70%
Test for overall effect: Z = 8.79 (P < 0.00001)
Test for subgroup differences: Not applicable
0.2 0.5 1 2 5
Favors fluocinolone Favors standard of care
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Analysis 1.3. Comparison 1 Fluocinolone implant versus standard-of-care, Outcome 3 Elevated intraocular
pressure > 10 mmHg cumulative through 24 months.
Review: Corticosteroid implants for chronic non-infectious uveitis
Comparison: 1 Fluocinolone implant versus standard-of-care
Outcome: 3 Elevated intraocular pressure > 10 mmHg cumulative through 24 months
Study or subgroup Fluocinolone implant Standard of care Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Kempen 2011 122/235 36/230 82.8 % 3.32 [ 2.40, 4.59 ]
Pavesio 2010 37/66 8/74 17.2 % 5.19 [ 2.61, 10.32 ]
Total (95% CI) 301 304 100.0 % 3.64 [ 2.71, 4.87 ]
Total events: 159 (Fluocinolone implant), 44 (Standard of care)
Heterogeneity: Chi2 = 1.33, df = 1 (P = 0.25); I2 =25%
Test for overall effect: Z = 8.65 (P < 0.00001)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favors fluocinolone Favors standard of care
Analysis 1.4. Comparison 1 Fluocinolone implant versus standard-of-care, Outcome 4 Endophthalmitis
through 24 months.
Review: Corticosteroid implants for chronic non-infectious uveitis
Comparison: 1 Fluocinolone implant versus standard-of-care
Outcome: 4 Endophthalmitis through 24 months
Study or subgroup Fluocinolone implant Standard of care Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Kempen 2011 3/237 0/230 51.8 % 6.79 [ 0.35, 130.81 ]
Pavesio 2010 3/66 0/74 48.2 % 7.84 [ 0.41, 148.94 ]
Total (95% CI) 303 304 100.0 % 7.30 [ 0.91, 58.72 ]
Total events: 6 (Fluocinolone implant), 0 (Standard of care)
Heterogeneity: Chi2 = 0.00, df = 1 (P = 0.95); I2 =0.0%
Test for overall effect: Z = 1.87 (P = 0.062)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favors fluocinolone Favors standard of care
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Analysis 1.5. Comparison 1 Fluocinolone implant versus standard-of-care, Outcome 5 Retinal detachment
through 24 months.
Review: Corticosteroid implants for chronic non-infectious uveitis
Comparison: 1 Fluocinolone implant versus standard-of-care
Outcome: 5 Retinal detachment through 24 months
Study or subgroup Fluocinolone implant Standard of care Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Kempen 2011 5/236 1/230 34.9 % 4.87 [ 0.57, 41.39 ]
Pavesio 2010 1/66 2/74 65.1 % 0.56 [ 0.05, 6.04 ]
Total (95% CI) 302 304 100.0 % 2.07 [ 0.51, 8.40 ]
Total events: 6 (Fluocinolone implant), 3 (Standard of care)
Heterogeneity: Chi2 = 1.77, df = 1 (P = 0.18); I2 =44%
Test for overall effect: Z = 1.02 (P = 0.31)
Test for subgroup differences: Not applicable
0.02 0.1 1 10 50
Favors fluocinolone Favors standard of care
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Analysis 1.6. Comparison 1 Fluocinolone implant versus standard-of-care, Outcome 6 IOP-lowering surgery
performed through 24 months.
Review: Corticosteroid implants for chronic non-infectious uveitis
Comparison: 1 Fluocinolone implant versus standard-of-care
Outcome: 6 IOP-lowering surgery performed through 24 months
Study or subgroup Fluocinolone implant Standard of care Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Kempen 2011 61/233 8/226 81.2 % 7.40 [ 3.62, 15.10 ]
Pavesio 2010 14/66 2/74 18.8 % 7.85 [ 1.85, 33.26 ]
Total (95% CI) 299 300 100.0 % 7.48 [ 3.94, 14.19 ]
Total events: 75 (Fluocinolone implant), 10 (Standard of care)
Heterogeneity: Chi2 = 0.01, df = 1 (P = 0.94); I2 =0.0%
Test for overall effect: Z = 6.16 (P < 0.00001)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favors fluocinolone Favors standard of care
Analysis 1.7. Comparison 1 Fluocinolone implant versus standard-of-care, Outcome 7 Hypotony through 24
months.
Review: Corticosteroid implants for chronic non-infectious uveitis
Comparison: 1 Fluocinolone implant versus standard-of-care
Outcome: 7 Hypotony through 24 months
Study or subgroup Fluocinolone implant Standard of care Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Kempen 2011 19/228 13/218 93.4 % 1.40 [ 0.71, 2.76 ]
Pavesio 2010 13/66 1/74 6.6 % 14.58 [ 1.96, 108.42 ]
Total (95% CI) 294 292 100.0 % 2.27 [ 1.24, 4.14 ]
Total events: 32 (Fluocinolone implant), 14 (Standard of care)
Heterogeneity: Chi2 = 5.25, df = 1 (P = 0.02); I2 =81%
Test for overall effect: Z = 2.67 (P = 0.0076)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favors fluocinolone Favors standard of care
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A D D I T I O N A L T A B L E S
Table 1. Secondary outcomes
Outcome
or
subgroup
Measured
by
Study Fluocinolone implant group Standard-of-care therapy group Effect estimate
1
Mean SD Number of
eyes
Mean SD Number of
eyes
(Positive value
favoring
implant)
Mean change in visual acuity
At 12
months
logMAR Kempen
2011
4.61 1.38 215 3.33 1.23 225 MD 1.29, 95%
CI -2.32 to 5.01
At 24
months
logMAR Kempen
2011
6.03 1.41 212 3.23 1.41 223 MD 2.79, 95%
CI -1.16 to 6.88
At 12
months
logMAR Pavesio
2010
Did not report the distance between the participants and the charts during the visual acuity
assessment
At 24
months
logMAR Pavesio
2010
Did not report the distance between the participants and the charts during the visual acuity
assessment
Mean change in quality of life*
At 12
months
NEI-VFQ Kempen
2011
12.13 1.60 NR 4.86 1.38 NR MD 7.29, 95%
CI 3.11 to 11.
42
At 24
months
NEI-VFQ Kempen
2011
11.44 1.67 NR 6.80 1.58 NR MD 4.64, 95%
CI 0.14 to 9.15
1Statistical method used was mean difference using fixed-effect model.
*The unit of analysis was the person.
CI: confidence interval
MD: mean difference
NEI-VFQ: National Eye Institute Visual Functioning Questionnaire
NR: not reported
SD: standard deviation
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A P P E N D I C E S
Appendix 1. CENTRAL search strategy
#1 MeSH descriptor: [Uveitis] explode all trees
#2 uveiti*
#3 MeSH descriptor: [Panuveitis] explode all trees
#4 Panuveitis
#5 MeSH descriptor: [Ophthalmia, Sympathetic] explode all trees
#6 (Ophthalm* near/2 Sympathetic)
#7 MeSH descriptor: [Pars Planitis] explode all trees
#8 Pars Planitis
#9 MeSH descriptor: [Panophthalmitis] explode all trees
#10 Panophthalmiti*
#11 MeSH descriptor: [Uveomeningoencephalitic Syndrome] explode all trees
#12 (Uveomeningoencephaliti* or Vogt Koyanagi Harada or VKH or fuch or Harada disease or harada syndrome or vogt koyanagi
disease)
#13 MeSH descriptor: [Behcet Syndrome] explode all trees
#14 (behcet* or triple symptom complex)
#15 MeSH descriptor: [Iridocyclitis] explode all trees
#16 (Iridocycliti* or Heterochromic Cycliti* or anterior scleritis)
#17 MeSH descriptor: [Iritis] explode all trees
#18 Iriti*
#19 Choroiditis
#20 (choroiditi* or retinochoroiditi* or chorioretinitis)
#21 (Blau* syndrome or familial juvenile systemic granulomatosis or Jabs disease)
#22 (Reiter* disease or reiter* syndrome or conjunctivo urethro synovial or urethrooculosynovial syndrome or uroarthritis)
#23 (uveoretinitis or uveo retinitis)
#24 vitritis*
#25 MeSH descriptor: [Retinitis] explode all trees
#26 retinitis or neuroretinitis
#27 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #
20 or #21 or #22 or #23 or #24 or #25 or #26
#28 MeSH descriptor: [Fluocinolone Acetonide] explode all trees
#29 (Fluocinolone or Fluortriamcinolone or Synalar or Synemol or Synamol or Alvadermo or Capex or “Co Fluocin” or Cortiespec or
Gelidina or Flucinar or Fluocid or Fluodermo or Fluonid or Fluotrex or Flurosyn or Flusolgen or Jellin or Jellisoft or “Derma Smooth
FS” or “67-73-2”)
#30 MeSH descriptor: [Dexamethasone] explode all trees
#31 (Dexamethasone* or “50-02-2” or Millicorten* or maxidex* or decaspray* or dexpak* or dexasone* or oradexon* or decaject* or
hexadecadrol* or hexadrol* or methylfluorprednisolone* or decameth*)
#32 retisert*
#33 MeSH descriptor: [Drug Implants] explode all trees
#34 MeSH descriptor: [Drug Delivery Systems] explode all trees
#35 (Device* or implant* or shunt* or valve* or tube*)
#36 #28 or #29 or #30 or #31 or #32 or #33 or #34 or #35
#37 #27 and #36
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Appendix 2. MEDLINE (OvidSP) search strategy
1. Randomized Controlled Trial.pt.
2. Controlled Clinical Trial.pt.
3. (randomized or randomised).ab,ti.
4. placebo.ab,ti.
5. drug therapy.fs.
6. randomly.ab,ti.
7. trial.ab,ti.
8. groups.ab,ti.
9. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8
10. exp animals/ not humans.sh.
11. 9 not 10
12. exp Uveitis/
13. uveiti*.tw.
14. exp Panuveitis/
15. Panuveitis.tw.
16. exp Ophthalmia, Sympathetic/
17. (Ophthalm* adj2 Sympathetic).tw.
18. exp Pars Planitis/
19. Pars Planitis.tw.
20. exp Panophthalmitis/
21. Panophthalmiti*.tw.
22. exp Uveomeningoencephalitic Syndrome/
23. (Uveomeningoencephaliti* or Vogt Koyanagi Harada or VKH or fuch or Harada disease or harada syndrome or vogt koyanagi
disease).tw.
24. exp Behcet Syndrome/
25. (behcet* or triple symptom complex).tw.
26. exp Iridocyclitis/
27. (Iridocycliti* or Heterochromic Cycliti* or anterior scleritis).tw.
28. exp Iritis/
29. Iriti*.tw.
30. exp Choroiditis/
31. (choroiditi* or retinochoroiditi* or chorioretinitis).tw.
32. (Blau* syndrome or familial juvenile systemic granulomatosis or Jabs disease).tw.
33. (Reiter* disease or reiter* syndrome or conjunctivo urethro synovial or urethrooculosynovial syndrome or uroarthritis).tw.
34. (uveoretinitis or uveo retinitis).tw.
35. vitritis*.tw.
36. exp Retinitis/
37. (retinitis or neuroretinitis).tw.
38. or/12-37
39. exp Fluocinolone Acetonide/
40. (Fluocinolone or Fluortriamcinolone or Synalar or Synemol or Synamol or Alvadermo or Capex or Co-Fluocin or Cortiespec or
Gelidina or Flucinar or Fluocid or Fluodermo or Fluonid or Fluotrex or Flurosyn or Flusolgen or Jellin or Jellisoft or Derma Smooth
FS or 67-73-2).tw.
41. exp Dexamethasone/
42. (Dexamethasone* or 50-02-2 or Millicorten* or maxidex* or decaspray* or dexpak* or dexasone* or oradexon* or decaject* or
hexadecadrol* or hexadrol* or methylfluorprednisolone* or decameth*).tw.
43. retisert*.tw.
44. exp Drug Implants/
45. exp Absorbable Implants/
46. exp Drug Delivery Systems/
47. (Device* or implant* or shunt* or valve* or tube*).tw.
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48. 39 or 40 or 41 or 42 or 43 or 44 or 45 or 46 or 47
49. or/39-48
50. 11 and 38 and 49
51. ..dedup 50
The search filter for trials at the beginning of the MEDLINE strategy is from the published paper by Glanville et al (Glanville 2006).
Appendix 3. EMBASE.com search strategy
#1 ’randomized controlled trial’/exp
#2 ’randomization’/exp
#3 ’double blind procedure’/exp
#4 ’single blind procedure’/exp
#5 random*:ab,ti
#6 #1 OR #2 OR #3 OR #4 OR #5
#7 ’animal’/exp OR ’animal experiment’/exp
#8 ’human’/exp
#9 #7 AND #8
#10 #7 NOT #9
#11 #6 NOT #10
#12 ’clinical trial’/exp
#13 (clin* NEAR/3 trial*):ab,ti
#14 ((singl* OR doubl* OR trebl* OR tripl*) NEAR/3 (blind* OR mask*)):ab,ti
#15 ’placebo’/exp
#16 placebo*:ab,ti
#17 random*:ab,ti
#18 ’experimental design’/exp
#19 ’crossover procedure’/exp
#20 ’control group’/exp
#21 ’latin square design’/exp
#22 #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21
#23 #22 NOT #10
#24 #23 NOT #11
#25 ’comparative study’/exp
#26 ’evaluation’/exp
#27 ’prospective study’/exp
#28 control*:ab,ti OR prospectiv*:ab,ti OR volunteer*:ab,ti
#29 #25 OR #26 OR #27 OR #28
#30 #29 NOT #10
#31 #30 NOT (#11 OR #23)
#32 #11 OR #24 OR #31
#33 ’uveitis’/exp
#34 uveiti*:ab,ti
#35 ’autoimmune uveitis’/exp
#36 ’behcet disease’/exp
#37 behcet*:ab,ti OR ’triple symptom complex’:ab,ti
#38 ’blau syndrome’/exp
#39 (blau* NEXT/1 syndrome):ab,ti OR ’familial juvenile systemic granulomatosis’:ab,ti OR ’jabs disease’:ab,ti
#40 ’choroiditis’/exp
#41 choroiditi*:ab,ti OR chorioiditi*:ab,ti
#42 ’chorioretinitis’/exp
#43 retinochoroiditi*:ab,ti OR chorioretiniti*:ab,ti
#44 ’vogt koyanagi syndrome’/exp
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#45 uveomeningoencephaliti*:ab,ti OR ’vogt koyanagi harada’:ab,ti OR vkh:ab,ti OR fuch:ab,ti OR ’harada disease’:ab,ti OR ’harada
syndrome’:ab,ti OR ’vogt koyanagi disease’:ab,ti
#46 ’intermediate uveitis’/exp
#47 ’pars planitis’:ab,ti
#48 ’iridocyclitis’/exp
#49 iridocycliti*:ab,ti OR (heterochromic NEXT/1 cycliti*):ab,ti OR ’anterior scleritis’:ab,ti
#50 ’iritis’/exp
#51 iriti*:ab,ti
#52 ’kirisawa uveitis’/exp
#53 ’reiter syndrome’/exp
#54 (reiter* NEXT/1 disease):ab,ti OR (reiter* NEXT/1 syndrome):ab,ti OR ’conjunctivo urethro synovial’:ab,ti OR ’urethroocu-
losynovial syndrome’:ab,ti OR uroarthritis:ab,ti
#55 ’sympathetic ophthalmia’/exp
#56 (ophthalm* NEXT/2 sympathetic):ab,ti
#57 ’uveoretinitis’/exp
#58 uveoretinitis:ab,ti OR ’uveo retinitis’:ab,ti
#59 ’vitritis’/exp
#60 vitritis*:ab,ti
#61 panuveitis:ab,ti
#62 panophthalmiti*:ab,ti
#63 ’retinitis’/exp
#64 retinitis:ab,ti OR neuroretinitis:ab,ti
#65 #33 OR #34 OR #35 OR #36 OR #37 OR #38 OR #39 OR #40 OR #41 OR #42 OR #43 OR #44 OR #45 OR #46 OR #47
OR #48 OR #49 OR #50 OR #51 OR #52 OR #53 OR #54 OR #55 OR #56 OR #57 OR #58 OR #59 OR #60 OR #61 OR #62
OR #63 OR #64
#66 ’fluocinolone acetonide’/exp
#67 fluocinolone:tn,rn,ab,ti OR adermina:tn,rn,ab,ti OR alfabios:tn,rn,ab,ti OR ’alvadermo fuerte’:tn,rn,ab,ti OR aplosyn:tn,rn,ab,ti
OR capex:tn,rn,ab,ti OR cervicum:tn,rn,ab,ti OR cinolon:tn,rn,ab,ti OR clofeet:tn,rn,ab,ti OR cortilona:tn,rn,ab,ti OR cremisona:
tn,rn,ab,ti OR cynozet:tn,rn,ab,ti OR ’derma smooth’:tn,rn,ab,ti OR ’derma smoothe’:tn,rn,ab,ti OR dermalar:tn,rn,ab,ti OR der-
moflam:tn,rn,ab,ti OR dermoran:tn,rn,ab,ti OR esacinone:tn,rn,ab,ti OR flozet:tn,rn,ab,ti OR fluciderm:tn,rn,ab,ti OR flulone*:
tn,rn,ab,ti OR fluocet:tn,rn,ab,ti OR fluocinolon*:tn,rn,ab,ti OR fluoderm:tn,rn,ab,ti OR fluolar:tn,rn,ab,ti OR fluonid:tn,rn,ab,ti
OR fluonide:tn,rn,ab,ti OR fluotrex:tn,rn,ab,ti OR fluquinol:tn,rn,ab,ti OR flurosyn:tn,rn,ab,ti OR flusonlen:tn,rn,ab,ti OR flu-
zon:tn,rn,ab,ti OR ’fs shampoo’:tn,rn,ab,ti OR fusalar:tn,rn,ab,ti OR iluvien:tn,rn,ab,ti OR inoderm:tn,rn,ab,ti OR jellin:tn,rn,ab,ti
OR localyn:tn,rn,ab,ti OR luci:tn,rn,ab,ti OR medidur:tn,rn,ab,ti OR neosynalar:tn,rn,ab,ti OR psoranide:tn,rn,ab,ti OR radiocin:
tn,rn,ab,ti OR retisert:tn,rn,ab,ti OR ’rs 1401 at’:tn,rn,ab,ti OR ’rs1401 at’:tn,rn,ab,ti OR supralan:tn,rn,ab,ti OR synalar:tn,rn,ab,ti
OR synandone:tn,rn,ab,ti OR synemol:tn,rn,ab,ti OR synotic:tn,rn,ab,ti OR syntopic:tn,rn,ab,ti OR trisyn:tn,rn,ab,ti OR ’67 73 2’:
tn,rn,ab,ti
#68 ’dexamethasone’/exp
#69 dexamethasone:tn,rn,ab,ti OR adrecort:tn,rn,ab,ti OR adrenocot:tn,rn,ab,ti OR ’aeroseb dex’:tn,rn,ab,ti OR aflucoson:tn,rn,ab,ti
OR aflucosone:tn,rn,ab,ti OR alfalyl:tn,rn,ab,ti OR anaflogistico:tn,rn,ab,ti OR arcodexan:tn,rn,ab,ti OR arcodexane:tn,rn,ab,ti
OR artrosone:tn,rn,ab,ti OR azium:tn,rn,ab,ti OR bidexol:tn,rn,ab,ti OR calonat:tn,rn,ab,ti OR cebedex:tn,rn,ab,ti OR cetadexon:
tn,rn,ab,ti OR colofoam:tn,rn,ab,ti OR corsona:tn,rn,ab,ti OR cortastat:tn,rn,ab,ti OR cortidex:tn,rn,ab,ti OR cortidexason:tn,rn,ab,ti
OR cortidrona:tn,rn,ab,tiOR cortidrone:tn,rn,ab,tiOR cortisumman:tn,rn,ab,tiOR ’dacortina fuerte’:tn,rn,ab,tiOR ’dacortine fuerte’:
tn,rn,ab,ti OR dalalone:tn,rn,ab,ti OR danasone:tn,rn,ab,ti OR ’de-sone la’:tn,rn,ab,ti OR decacortin:tn,rn,ab,ti OR decadeltosona:
tn,rn,ab,ti OR decadeltosone:tn,rn,ab,ti OR decaderm:tn,rn,ab,ti OR decadion:tn,rn,ab,ti OR decadran:tn,rn,ab,ti OR decadron:
tn,rn,ab,ti OR decadronal:tn,rn,ab,ti OR decadrone:tn,rn,ab,ti OR decaesadril:tn,rn,ab,ti OR decaject:tn,rn,ab,ti OR decametha-
sone:tn,rn,ab,ti OR decasone:tn,rn,ab,ti OR decaspray:tn,rn,ab,ti OR decasterolone:tn,rn,ab,ti OR decdan:tn,rn,ab,ti OR decilone:
tn,rn,ab,ti OR decofluor:tn,rn,ab,ti OR dectancyl:tn,rn,ab,ti OR dekacort:tn,rn,ab,ti OR delladec:tn,rn,ab,ti OR deltafluoren:
tn,rn,ab,ti OR deltafluorene:tn,rn,ab,ti OR dergramin:tn,rn,ab,ti OR deronil:tn,rn,ab,ti OR desacort:tn,rn,ab,ti OR desacortone:
tn,rn,ab,ti OR desadrene:tn,rn,ab,ti OR desalark:tn,rn,ab,ti OR desameton:tn,rn,ab,ti OR desametone:tn,rn,ab,ti OR desigdron:
tn,rn,ab,ti OR ’dexa-p’:tn,rn,ab,ti OR ’dexa cortisyl’:tn,rn,ab,ti OR ’dexa dabrosan’:tn,rn,ab,ti OR ’dexa korti’:tn,rn,ab,ti OR ’dexa
scherosan’:tn,rn,ab,tiOR ’dexa scherozon’:tn,rn,ab,tiOR ’dexa scherozone’:tn,rn,ab,tiOR ’dexacen4’:tn,rn,ab,tiORdexachel:tn,rn,ab,ti
OR dexacort:tn,rn,ab,ti OR dexacortal:tn,rn,ab,ti OR dexacorten:tn,rn,ab,ti OR dexacortin:tn,rn,ab,ti OR dexacortisyl:tn,rn,ab,ti OR
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dexadabroson:tn,rn,ab,ti OR dexadecadrol:tn,rn,ab,ti OR dexadrol:tn,rn,ab,ti OR dexagel:tn,rn,ab,ti OR dexagen:tn,rn,ab,ti OR dex-
ahelvacort:tn,rn,ab,ti OR dexakorti:tn,rn,ab,ti OR dexalien:tn,rn,ab,ti OR dexalocal:tn,rn,ab,ti OR dexame:tn,rn,ab,ti OR dexam-
ecortin:tn,rn,ab,tiORdexameson:tn,rn,ab,tiORdexamesone:tn,rn,ab,tiORdexametason:tn,rn,ab,tiOR dexametasone:tn,rn,ab,tiOR
dexameth:tn,rn,ab,ti OR dexamethason:tn,rn,ab,ti OR dexamethazon:tn,rn,ab,ti OR dexamethazone:tn,rn,ab,ti OR dexamethonium:
tn,rn,ab,ti OR dexamonozon:tn,rn,ab,ti OR dexan:tn,rn,ab,ti OR dexane:tn,rn,ab,ti OR dexano:tn,rn,ab,ti OR dexapot:tn,rn,ab,ti
OR dexascheroson:tn,rn,ab,ti OR dexascherozon:tn,rn,ab,ti OR dexascherozone:tn,rn,ab,ti OR dexason:tn,rn,ab,ti OR dexasone:
tn,rn,ab,ti OR dexinoral:tn,rn,ab,ti OR dexionil:tn,rn,ab,ti OR dexmethsone:tn,rn,ab,ti OR dexona:tn,rn,ab,ti OR dexone:tn,rn,ab,ti
OR ’dexpak taperpak’:tn,rn,ab,ti OR dextelan:tn,rn,ab,ti OR dextrasone:tn,rn,ab,ti OR dezone:tn,rn,ab,ti OR dibasona:tn,rn,ab,ti
OR doxamethasone:tn,rn,ab,ti OR esacortene:tn,rn,ab,ti OR ’ex s1’:tn,rn,ab,ti OR exadion:tn,rn,ab,ti OR exadione:tn,rn,ab,ti OR
firmalone:tn,rn,ab,ti OR ’fluormethyl prednisolone’:tn,rn,ab,ti OR ’fluormethylprednisolon’:tn,rn,ab,ti OR fluormethylprednisolone:
tn,rn,ab,ti OR fluormone:tn,rn,ab,ti OR fluorocort:tn,rn,ab,ti OR fluorodelta:tn,rn,ab,ti OR fluoromethylprednisolone:tn,rn,ab,ti
OR fortecortin:tn,rn,ab,ti OR gammacorten:tn,rn,ab,ti OR gammacortene:tn,rn,ab,ti OR grosodexon:tn,rn,ab,ti OR grosodexone:
tn,rn,ab,ti OR hexadecadiol:tn,rn,ab,ti OR hexadecadrol:tn,rn,ab,ti OR hexadiol:tn,rn,ab,ti OR hexadrol:tn,rn,ab,ti OR isnacort:
tn,rn,ab,ti OR ’isopto dex’:tn,rn,ab,ti OR ’isopto maxidex’:tn,rn,ab,ti OR isoptodex:tn,rn,ab,ti OR isoptomaxidex:tn,rn,ab,ti OR
’lokalison f ’:tn,rn,ab,ti OR loverine:tn,rn,ab,ti OR luxazone:tn,rn,ab,ti OR marvidione:tn,rn,ab,ti OR maxidex:tn,rn,ab,ti OR medi-
amethasone:tn,rn,ab,ti ORmegacortin:tn,rn,ab,ti ORmephameson:tn,rn,ab,ti ORmephamesone:tn,rn,ab,ti ORmetasolon:tn,rn,ab,ti
OR metasolone:tn,rn,ab,ti OR ’methazon ion’:tn,rn,ab,ti OR ’methazone ion’:tn,rn,ab,ti OR methazonion:tn,rn,ab,ti OR methazo-
nione:tn,rn,ab,ti OR ’metisone lafi’:tn,rn,ab,ti OR mexasone:tn,rn,ab,ti OR millicorten:tn,rn,ab,ti OR millicortenol:tn,rn,ab,ti OR
’mk 125’:tn,rn,ab,ti OR ’mk125’:tn,rn,ab,ti OR mymethasone:tn,rn,ab,ti OR nisomethasona:tn,rn,ab,ti OR novocort:tn,rn,ab,ti OR
’nsc 34521’:tn,rn,ab,ti OR ’nsc34521’:tn,rn,ab,ti OR ’oftan-dexa’:tn,rn,ab,ti OR opticorten:tn,rn,ab,ti OR opticortinol:tn,rn,ab,ti
OR oradexan:tn,rn,ab,ti OR oradexon:tn,rn,ab,ti OR oradexone:tn,rn,ab,ti OR orgadrone:tn,rn,ab,ti OR ozurdex:tn,rn,ab,ti OR pi-
dexon:tn,rn,ab,ti OR policort:tn,rn,ab,ti OR posurdex:tn,rn,ab,ti OR ’predni-f ’:tn,rn,ab,ti OR ’prednisolone f ’:tn,rn,ab,ti OR prodex-
ona:tn,rn,ab,ti OR prodexone:tn,rn,ab,ti OR sanamethasone:tn,rn,ab,ti OR santenson:tn,rn,ab,ti OR santeson:tn,rn,ab,ti OR sawa-
sone:tn,rn,ab,ti OR solurex:tn,rn,ab,ti OR spoloven:tn,rn,ab,ti OR sterasone:tn,rn,ab,ti OR thilodexine:tn,rn,ab,ti OR triamcimetil:
tn,rn,ab,ti OR vexamet:tn,rn,ab,ti OR visumetazone:tn,rn,ab,ti OR visumethazone:tn,rn,ab,ti OR ’50-02-2’:tn,rn,ab,ti
#70 ’drug delivery system’/exp
#71 ’drug implant’/exp
#72 ’biodegradable implant’/exp
#73 device*:ab,ti OR implant*:ab,ti OR shunt*:ab,ti OR valve*:ab,ti OR tube*:ab,ti
#74 #66 OR #67 OR #68 OR #69 OR #70 OR #71 OR #72 OR #73
#75 #34 AND #65 AND #74
Appendix 4. PubMed search strategy
1. ((randomized controlled trial[pt]) OR (controlled clinical trial[pt]) OR (randomised[tiab] OR randomized[tiab]) OR (placebo[tiab])
OR (drug therapy[sh]) OR (randomly[tiab]) OR (trial[tiab]) OR (groups[tiab])) NOT (animals[mh] NOT humans[mh])
2. uveiti*[tw] OR Panuveitis[tw] OR (Ophthalm*[tw] AND Sympathetic[tw]) OR Pars Planitis[tw] OR Panophthalmiti*[tw] OR
Uveomeningoencephaliti*[tw] OR Vogt Koyanagi Harada[tw] OR VKH[tw] OR fuch[tw] OR Harada disease[tw] OR harada syn-
drome[tw] OR vogt koyanagi disease[tw] OR behcet*[tw] OR triple symptom complex[tw] OR Iridocycliti*[tw] OR Heterochromic
Cycliti*[tw] OR anterior scleritis[tw] OR Iriti*[tw] OR choroiditi*[tw] OR retinochoroiditi*[tw] OR chorioretinitis[tw] OR Blau*
syndrome[tw] OR familial juvenile systemic granulomatosis[tw] OR Jabs disease[tw] OR Reiter* disease[tw] OR reiter* syndrome[tw]
OR conjunctivo urethro synovial[tw] OR urethrooculosynovial syndrome[tw] OR uroarthritis[tw] OR uveoretinitis[tw] OR uveo
retinitis[tw] OR vitritis*[tw] OR retinitis[tw] OR neuroretinitis[tw]
3. Fluocinolone[tw]ORFluortriamcinolone[tw]ORSynalar[tw]ORSynemol[tw]ORSynamol[tw]ORAlvadermo[tw]ORCapex[tw]
OR Co Fluocin[tw] OR Cortiespec[tw] OR Gelidina[tw] OR Flucinar[tw] OR Fluocid[tw] OR Fluodermo[tw] OR Fluonid[tw] OR
Fluotrex[tw] OR Flurosyn[tw] OR Flusolgen[tw] OR Jellin[tw] OR Jellisoft[tw] OR Derma Smooth FS[tw] OR 67-73-2[tw] OR
Dexamethasone*[tw] OR 50-02-2[tw] ORMillicorten*[tw] ORmaxidex*[tw] OR decaspray*[tw] OR dexpak*[tw] OR dexasone*[tw]
OR oradexon*[tw] OR decaject*[tw] OR hexadecadrol*[tw] OR hexadrol*[tw] OR methylfluorprednisolone*[tw] OR decameth*[tw]
OR retisert*[tw] OR Device*[tw] OR implant*[tw] OR shunt*[tw] OR valve*[tw] OR tube[tw] OR tubes[tw]
4. #2 AND #3
5. #1 AND #4
6. MEDLINE[sb]
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7. #5 NOT #6
Appendix 5. LILACS search strategy
((Uveitis or Uveítis or Uveíte or MH:C11.941.879$ or Panuveitis or Panuveítis or Panuveíte or “Ophthalmia Sympathetic” or
“Oftalmía Simpática” or “Oftalmia Simpática” or “Pars Planitis” or “Pars Planite” or “Panophthalmitis” or “Panoftalmitis” or
“Panoftalmite” or MH:C01.252.354.900.675$ or MH:C01.539.375.354.900.675$ or MH:C01.539.375.450.900.675$ or MH:
C01.703.343.900.675$ or MH:C11.294.354.900.675$ or MH:C11.294.450.900.675$ or “Uveomeningoencephalitic Syndrome” or
“Síndrome Uveomeningoencefálico” or “Síndrome Uveomeningoencefálica” or MH:C10.114.843$ or MH:C10.228.228.553.900$
or MH:C20.111.258.925$ or Uveomeningoencephalitis or “Vogt Koyanagi Harada” or “Harada disease” or “harada syndrome” or
“vogt koyanagi disease” or “Behcet syndrome” or “Síndrome de Behçet” or MH:C07.465.075$ or MH:C14.907.940.100$ or MH:
C17.800.862.150$ or “triple symptom complex” or Iridocyclitis or Iridociclitis or Iridociclite or MH:C11.941.375.360$ or “Hete-
rochromic Cyclitis” or MH:C11.941.160.478$ or chorioretinitis or Retinitis or Retinite or MH:C11.768.773$) AND (“Fluocinolone
Acetonide” or “Fluocinolona Acetonida” or MH:D04.808.745.432.370$ or MH:D04.808.908.394$ or Dexamethasone or Dexameta-
sona or MH:D04.808.745.432.769.344$ or MH:D04.808.908.238$ or MH:D26.255.210.315$ or MH:D27.720.280.210.315$ or
MH:E07.695.025$ or “Drug Delivery Systems” or “Sistemas de Liberación de Medicamentos” or “Sistemas de Liberação de Medica-
mentos” or MH:E02.319.300$ or Device$ or implant$ or shunt$ or valve$ or tube or tubes))
Appendix 6. metaRegister of Controlled Trials search strategy
(uveitis OR panuveitis OR choroiditis OR pars planitis OR panophthalmitis OR uveomeningoencephalitic OR behcetOR iridocyclitis
OR iritis OR retinitis) AND (fluocinolone OR dexamethasone OR retisert* OR device* OR implant* OR shunt* OR valve* OR
tube*)
Appendix 7. ClinicalTrials.gov search strategy
(uveitis OR panuveitis OR choroiditis OR pars planitis OR panophthalmitis OR uveomeningoencephalitic OR behcetOR iridocyclitis
OR iritis OR retinitis) AND (fluocinolone OR dexamethasone OR retisert OR device OR implant OR shunt OR valve OR tube)
Appendix 8. ICTRP search strategy
uveitis AND fluocinolone OR uveitis AND dexamethasone OR uveitis AND retisert OR uveitis AND device OR uveitis AND
implant OR uveitis AND shunt OR uveitis AND valve OR uveitis AND tube OR panuveitis AND fluocinolone OR panuveitis AND
dexamethasone OR panuveitis AND retisert OR panuveitis AND device OR panuveitis AND implant OR panuveitis AND shunt
OR panuveitis AND valve OR panuveitis AND tube OR choroiditis AND fluocinolone OR choroiditis AND dexamethasone OR
choroiditis AND retisert OR choroiditis AND device OR choroiditis AND implant OR choroiditis AND shunt OR choroiditis AND
valve OR choroiditis AND tube OR pars planitis AND fluocinolone OR pars planitis AND dexamethasone OR pars planitis AND
retisert OR pars planitis ANDdevice OR pars planitis AND implant OR pars planitis AND shunt OR pars planitis AND valve OR pars
planitis AND tube OR panophthalmitis AND fluocinolone OR panophthalmitis AND dexamethasone OR panophthalmitis AND
retisert OR panophthalmitis AND device OR panophthalmitis AND implant OR panophthalmitis AND shunt OR panophthalmitis
AND valve OR panophthalmitis AND tube
uveomeningoencephalitic ANDfluocinolone OR uveomeningoencephalitic ANDdexamethasone OR uveomeningoencephalitic AND
retisert OR uveomeningoencephalitic AND device OR uveomeningoencephalitic AND implant OR uveomeningoencephalitic AND
shunt OR uveomeningoencephalitic AND valve OR uveomeningoencephalitic AND tube OR behcet AND fluocinolone OR behcet
AND dexamethasone OR behcet AND retisert OR behcet AND device OR behcet AND implant OR behcet AND shunt OR behcet
AND valve OR behcet AND tube OR iridocyclitis AND fluocinolone OR iridocyclitis AND dexamethasone OR iridocyclitis AND
retisert OR iridocyclitis AND device OR iridocyclitis AND implant OR iridocyclitis AND shunt OR iridocyclitis AND valve OR
iridocyclitis AND tube OR iritis AND fluocinolone OR iritis AND dexamethasone OR iritis AND retisert OR iritis AND device OR
iritis AND implant OR iritis AND shunt OR iritis AND valve OR iritis AND tube OR retinitis AND fluocinolone OR retinitis AND
dexamethasone OR retinitis AND retisert OR retinitis AND device OR retinitis AND implant OR retinitis AND shunt OR retinitis
AND valve OR retinitis AND tube
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
In our protocol design phase, an age criterion greater than or equal to 18 years was created for practical reasons. In our initial full-
text review, no studies qualified for inclusion in our review due to this exclusion of participants younger than 18 years. We felt the
differences in the disease states and response to treatment of those 17 or younger who would otherwise qualify for the review would not
be systematically different from adults, and would not limit the generalizability of the review results. We therefore made the decision
to eliminate the age requirement.
In future revisions of the review, we plan to perform a subgroup analyses by age. For the current version of the review, we contacted
study authors, but were unable to obtain separate data for those under 18 and those over 18, therefore we were not able to perform a
subgroup analysis. Should study authors of future studies provide separate data for those age under 18 and those over 18 years, we will
perform a subgroup analysis.
In our protocol we also stated that we will not pursue meta-analysis of the selected studies when the I2 statistic was greater than
50% (substantial heterogeneity). We wanted to clarify that our initial intentions did not account for clinical and methodological
heterogeneity. Because we determined that the two included studies were clinical and methodologically similar, we combined data in
meta-analysis even when the I2 statistic was greater than 50%.
There was insufficient data to conduct a subgroup analyses by clinical heterogeneity. We defined clinical heterogeneity by types of
participants (i.e., baseline vision, baseline intraocular pressure, duration of prior therapy and diagnosis), interventions and outcomes
in each study. We will perform a subgroup analyses by clinical heterogeneity when there are sufficient data.
We were unable to conduct sensitivity analyses to determine the impact of exclusion of studies with lower methodological quality,
including exclusion of industry-funded studies and unpublished studies as there were too few included studies. When more studies are
included in future versions of this review and appropriate, we plan to conduct sensitivity analyses.
We also analyzed outcome data at 12 and 24 months rather than the prespecified six months, because this matched the primary
outcomes of the two included studies. We felt this permitted a more relevant point of comparison for these two therapies, especially
because many of the side effects of interest (for example cataract) are expected to take time to develop.
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